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Abstract 
Background: Reliable protection against nosocomial tuberculosis transmission in theatre 
depends on the appropriate use of filtering facepiece respirators (FFRs) with an N95 filter, as 
recommended by the Centers for Disease Control and Prevention.  
Aim: To describe anaesthetist compliance and comfort with the use of FFRs, followed by 
donning technique and fit tests outcomes. 
Design: Prospective, contextual, descriptive, two part study.  
Setting: Part 1 was done in a university affiliated department of anaesthesiology. Part 2 was 
a pilot study in the theatre complex of a 1200-bed tertiary-level academic hospital. 
Participants: Part 1 – anaesthetists in the department selected by convenience sampling 
(n=140). Part 2 – anaesthetists selected by stratified random sampling (10 male and 10 
female).  
Methods: In Part 1 a self-administered questionnaire was distributed. In Part 2 the donning 
technique was directly observed, corrected, then followed by qualitative fit testing with the 
single model and size FFR available. 
Results: Part 1 -Compliance with the use of the FFR was inadequate with a compliance score 
of 14.5 (SD 5.0) out of 25. FFRs are deemed to be uncomfortable (discomfort score of 9.9 
(SD 4.0) out of 21.) Part 2 - Of the 20 anaesthetists, six (30%), five males and one female, 
passed the fit test. 
Conclusions: Compliance with FFR use was poor and anaesthetists at the research 
institution found the FFRs uncomfortable. FFR donning technique was observed to be 
lacking. Research with a larger study group is required. Poor fit test results were most likely 
due to the availability of only one size and model of FFR. 
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Section 1: Review of the Literature 
1. 1 Introduction 
The tuberculosis (TB) epidemic remains a global challenge. The purpose of this literature 
review is to portray the background of anaesthetists’ vulnerability and the protection 
required against occupational TB transmission. 
An initial description of TB in South Africa is followed by the pathophysiology and 
transmission of TB. The context of drug resistant TB and the high prevalence of co-infection 
with HIV in South Africa are illuminated.   
The phenomenon of nosocomial transmission of TB is depicted, with emphasis on the risk of 
transmission to healthcare workers (HCWs). Guidelines for TB infection control in hospitals 
are described with an in depth exploration of personal respiratory protection devices, their 
history and classification, with specific focus on the filtering facepiece respirator (FFR). The 
importance of an impenetrable face seal is clarified together with methods to check the face 
seal such as the self-fit check and the fit test. Different fit tests and their procedures are 
described. 
Literature regarding the use of FFRs is organised into FFR performance, face fitting 
characteristics and HCW compliance with the use of the FFR.  A summary of where the FFR 
fits into the recommended international and South African infection control guidelines as 
well as local guidelines for infection control at Charlotte Maxeke Johannesburg Academic 
Hospital (CMJAH) follows. 
Anaesthetists are a vulnerable group of HCWs due to their proximity to patients with 
potentially undiagnosed TB. Anaesthetic manipulation may cause coughing, which results in 
aerosolisation of infectious droplets. The guidelines on the perioperative management of 
the patient with active TB are discussed. 
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1.2  TB in South Africa 
1.2.1  Incidence 
The World Health Organisation (WHO) estimated in 2014 there were 9.6 million new 
diagnoses of TB worldwide and that TB killed 1.5 million people globally. South Africa suffers 
severely with an estimated prevalence rate of 696 cases per 100 000 people weighed 
against the worldwide average of 133 cases per 100 000 people. (1) According to the WHO 
statistics an estimated 450 000 new cases of active TB were diagnosed in South Africa in 
2013. (2) The implication is that almost 1% of the 50 586 757 South African population (3) 
will develop active TB disease every year. (4) The consequences of TB are more far reaching 
than the morbidity and mortality numbers imply, because most TB patients are in the 
economically active population group of 15 - 64 years of age. (5) 
1.2.2  Pathophysiology and transmission 
The unique way that TB spreads from human to human is different to that of many other 
infectious pathogens, such as adenovirus or rhinovirus, where droplet spread happens by 
surface contact. (6)  Transmission is by airborne particles called droplet nuclei. When a 
person with active TB coughs, talks, sings or sneezes, these particles are expelled. One 
cough potentially produces 3000 droplet nuclei of 1 - 5 micrometres in diameter. This 
explains why pulmonary as well as laryngeal TB is highly contagious. When these droplet 
nuclei, containing 1 - 5 bacilli each, are inhaled the mycobacteria will begin to replicate in 
the recipient’s alveoli. Between 1 and 10 bacilli are infectious and can cause either latent or 
active disease. Of those with normal immunity who get infected, 10% will develop active 
disease (half of these in the first two years and half later on in life) and 90% will develop 
latent TB.  It is more probable that immune compromised individuals will develop active TB 
than those with normal immunity. (7) 
Direct sun- and ultraviolet light kill the tubercle bacillus. For that reason most transmission 
happens in dark and poorly ventilated areas. Droplet nuclei remain airborne for up to four 
hours. Close contact and prolonged exposure to contaminated air increase the risk of 
transmission. The higher the concentration of bacilli in the air, the higher the likelihood of 
TB transmission is. (7) 
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1.2.3  Relationship with HIV 
TB and HIV have been described as “synergistic pandemics”. (8) Advancing 
immunosuppression increases the host’s susceptibility to TB infection, which causes an 
escalation in the number of TB cases and complicates the natural course and pattern of 
disease. The diagnosis of TB becomes more challenging in cases of established HIV. (7) 
The Annual Performance Plan of 2012/13 - 2014/15 of the South African Department of 
Health states that 73% of patients with TB are also HIV positive. (9) Globally the WHO 
estimates this number to be around 77%. (1) It is reckoned that 10% of newly diagnosed HIV 
positive patients have undiagnosed TB. A patient with HIV has an annual risk of 10% of 
contracting TB, compared to an HIV negative patient’s lifetime risk of 10%. (7) 
Limited data is available regarding the incidence of HIV among patients presenting for 
surgery in South Africa. Approximately 20 – 25% of patients with HIV will need an operation 
during the course of their disease. (10) 
1.2.4  Multi-drug resistant TB and extensively drug-resistant TB 
Worldwide an estimated 3.3% of newly diagnosed cases and 20% of formerly treated cases 
are multi-drug resistant TB (MDR-TB). The WHO reports 4700 (3700 – 5900) notified cases of 
MDR-TB in South Africa in 2014. (1) Since 2006 extensively drug-resistant (XDR-TB) strains 
pose unparalleled public health challenges, especially when considered in the context of 
insufficient infection control practices. In 2010 there were 741 confirmed cases of XDR-TB, a 
disease that is exceptionally challenging and costly to treat and has a very high mortality. (7) 
It was previously thought that drug-resistant TB arises primarily from poor treatment 
adherence of drug-susceptible TB, but D’Souza et al (11) confirmed in Mumbai high levels of 
MDR-TB in treatment naïve individuals.  
1.3 Nosocomial TB 
1.3.1 TB and HCWs  
Healthcare facilities harbour high density populations of potentially contagious patients. 
Hospital acquired TB is a threat to other patients, and an important occupational hazard for 
HCWs who are often inadvertently exposed to undiagnosed TB infected patients.  It would 
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be unfeasible to calculate the absolute number of HCWs who get infected with TB in 
healthcare facilities, because by the time the diagnosis is made it may a considerable time 
since the incident of exposure. MDR- and XDR-TB amplify the daily perils HCWs face. (12)  
Menzies et al (13) conducted a systematic review to investigate the prevalence and 
incidence of TB among HCWs. Twelve studies from “low and middle income countries” from 
1960 - 2005 were included and it found “the median prevalence of latent TB infection” 
among HCWs from these countries to be 63% (range 33 – 79%.) The median prevalence 
from the eight studies from high income countries from 1992 - 2005 was 24% (range 4 – 
46%). In these countries latent TB infection was reliably related to occupational exposure. 
HCWs had disproportionately higher rates of active TB than the overall population. 
A meta-analysis by Baussano et al (14) used data extracted from 43 studies published from 
January 2005 to July 2010 to calculate the incidence rate ratio of TB infection among HCWs. 
Incidence rate ratio is explained as the difference in the risk of HCWs contracting TB 
compared to the risk of the overall population, indicating the fraction of TB infection in 
HCWs ascribed to healthcare setting exposure. The median estimated TB incidence rate 
ratio for countries with a high incidence of TB(>100 cases per 100 000 persons) was 5.4 
(interquartile range 1.7 - 9.1.) The analysis is limited by substantial heterogeneity between 
studies. No studies from South Africa were included.  
A study by the University Research Company (15) together with the Desmond Tutu 
Tuberculosis Centre investigated the magnitude and effect of occupational TB transmission 
on HCWs in 132 randomly selected South African healthcare facilities in 2008. They found 
South African HCWs have an average TB burden of 2%. This number may underreport the 
true incidence as only 40% of the facilities investigated had an employee TB screening 
program as well as an official occupational health policy in place. 
Tudor et al (16) conducted a retrospective cohort study from 2006 to 2010 in KwaZulu-Natal 
(KZN). They analysed 1313 HCWs’ files and found 112 (9%) diagnoses of TB during that time. 
The incidence rate of TB in HCWs in this sample was calculated as 1958 per 100 000 person-
years for 2010. The incidence of TB in South Africa at the time was 981 per 100 000. In the 
same study it was found that among the 112 HCWs with TB, 15 (13%) had MDR-TB. These 
5 
 
cases all occurred in HCWs who had never even worked in a TB ward. Thirteen of these 
HCWs died from TB disease. The poor quality of occupational clinic employee records is a 
limitation, as those with missing data were excluded. Some HCWs probably received their 
TB treatment outside the hospital and healthy employees did not have charts at the 
occupational health clinic, resulting in exclusion and inclusion bias. Risk factors for TB 
transmission elucidated by this study are HIV co-infection and a history of working in certain 
areas, including TB wards, paediatric wards, outpatient departments, stores or workshops. 
The prevalence of HIV among HCWs in South Africa was 16% in 2002. (17) Diabetes and 
other chronic illnesses are also potential risk factors (18), but this was not investigated. The 
authors advocate routine TB screening of HCWs, and improved infection control procedures 
throughout the hospital. 
O’Donnell et al (19) conducted a retrospective review of the charts of patients hospitalised 
for commencing MDR or XDR-TB treatment between 2003 and 2008 at a KZN referral 
hospital. A total of 231 HCWs (55% HIV positive) and 4151 non-HCWs (57% HIV positive) 
were included. The incidence of MDR-TB cases was estimated at 64.8 per 100 000 HCWs 
versus 11.9 per 100 000 “non–HCWs” (incidence rate ratio of 5.46). Occupational XDR-TB 
cases were estimated to have an incidence of 7.2 per 100 000 contrasted with 1.1 per 
100 000 in “non–HCWs” (incidence rate ratio of 6.69). As the setting studied was a TB 
referral hospital, the findings are subject to referral bias. 
Occupational TB has debilitating consequences for a HCW’s personal and professional life. 
Padayatchi et al (20) conducted a case series of five HIV negative doctors diagnosed with 
MDR-TB between 2000 and 2003 in South Africa, to determine the long-term psychosocial 
sequelae they suffered. Four of the five doctors (80%) decided to change the course of their 
career to work in specialist areas with negligible exposure to infectious patients. The fifth 
doctor suffered significant physical disability and has not been able to work since falling ill. 
All but one are still suffering from long term complications many years after completing 
treatment, including hearing impairment, deafness, tinnitus, anxiety, panic attacks, short 
term memory impairment, weakness, pain, neuropathy, loss of bladder and bowel control. 
Naidoo et al (21) explored individual “experiences, attitudes and perceptions” of 40 medical 
doctors who became infected with TB from 2007 to 2009 in KZN. Only two (5%) doctors 
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previously worked in a specialised TB clinic or ward. Enduring the treatment was difficult for 
27 (67.5%) doctors and 13 (32.5%) considered defaulting. Feelings of regret for choosing a 
career in clinical medicine were reported, as well as feelings of anger and resentment 
towards the patients who infected them. TB causes the South African healthcare system to 
lose HCWs to absenteeism, disability, demoralisation, hospitalisation and death. A HCW 
with active TB endangers both patients and colleagues. (22)  
1.3.2 TB infection control 
In South Africa it is the responsibility of the employer to provide a “reasonably safe 
workplace without risk to the health of employees” according to the Occupational Health 
and Safety Act No. 85 of 1993. (23) 
Methods to prevent TB transmission in healthcare environments were categorised by the 
Centers for Disease Control and Prevention (CDC) into three hierarchical components. (24) 
Firstly administrative measures aim to decrease the actual number of infectious droplets 
coughed into the air by prompt and accurate diagnosis, isolation and treatment of TB 
patients. Cough hygiene practices are an example of such respiratory source control. A 
coughing patient with active, untreated TB should use a surgical facemask in public spaces 
as a short-term measure.  
Secondly, environmental or architectural measures are aimed at eliminating the number of 
droplets present in the air. These measures include natural or mechanical ventilation 
systems and extractor turbines, sunlight or ultraviolet irradiation (25, 26), high-efficiency 
particulate air filters on exhaust air outlets and negative air ionisation. (2) 
 
The third component comprises personal protective equipment, specifically the correct and 
consistent use of personal respiratory protection devices. (27) As this is the focus of the 
study it will be discussed in more detail. 
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1.4 Respiratory protection devices 
Classification of respiratory protective devices 
Both masks and respirators have a facepiece that is tied to the user's head with straps or 
elastic bands. There is a clear distinction between masks and respirators. Masks are 
intended to protect the surroundings (such as the operating field) from particles and 
droplets produced by the user. Some surgical masks are specialised to protect the user from 
fluids splashes, but commonly masks do not reduce exposure of the wearer to bio aerosols 
and airborne particles. Masks cannot create a tight-fitting seal with one’s face. (29)  
A respirator is a device with the purpose of providing the wearer with a recognised level of 
respiratory protection from inhaling aerosolised contaminants. Two main categories of 
respirators exist: an air-supplied respirator delivers piped clean air from an unpolluted 
source, avoiding the harmful particles, fumes or gases completely. An air-purifying 
respirator allows polluted air to flow through a filter, thereby entrapping particulate matter 
and delivering the user with purified air distal to the filter. (30) Since the filters cannot be 
cleaned, respirators are either disposable, single-use models with a limited lifespan, or the 
more expensive reusable types with replaceable cartridges. 
Respirators can also be classified according to the part of the face that is covered. A full face 
respirator covers the entire face. The facepiece of a half face respirator should cover the 
nose, mouth and chin. The type of respirator required depends on the type of hazard to be 
encountered. Half face respirators should be used when there is no risk of harm to the eyes 
or skin. A quarter face mask covers the mouth and nose, it is not considered a respirator. 
(30) 
Respirators are used by the military, mining-, science- and health industry among others. A 
HCW needs an appropriate disposable air-purifying respirator that filters airborne particles, 
for personal respiratory protection against pathogens such as the infectious droplet nuclei 
carrying TB bacilli expelled by coughing patients. (28) 
Respirators can be further classified according to the filter used. The National Institute for 
Occupational Safety and Health (NIOSH) is the USA Government agency that certifies and 
approves respiratory protective devices for use in the workplace. The N, R and P 
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designations depict how oil resistant the filter is. The efficiency rating refers to the 
percentage of airborne particles that are filtered. Table 1.1 depicts the CDC classification on 
NIOSH-Approved Particulate filters. (31) 
Table 1.1 Classification according to the type of filter (31) 
Filter Oil resistance Efficiency rating 
(percentage of airborne particles filtered) 
N95 None At least 95% 
N99 None At least 99% 
N100 None At least 99.97% 
R95 Somewhat resistant At least 95% 
R99 Somewhat resistant  At least 99% 
R100 Somewhat resistant At least 99.97% 
P95 Strongly resistant At least 95% 
P99 Strongly resistant At least 99% 
P100 Strongly resistant At least 99.97% 
 
1.5  Filtering facepiece respirator 
The N95 FFR is the most affordable of the nine types of particulate FFRs that meet NIOSH 
requirements, and is thus the most popular in industrial and healthcare settings. (31, 32) In 
the literature this product is referred to as the FFR but colloquially it is often erroneously 
referred to as the “N95 mask”. The FFRs are available in variations of a firm cup shape as 
shown in figure 1.1, also called a tortoise-shell shape, and in a softer duck bill shape.  
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Figure 1.1 A filtering facepiece respirator (33) 
A NIOSH approved N95 FFR may not allow more than 5% penetration of aerosolised sodium 
chloride particles (diameter 0.3 micrometre) at a flow rate of 85 litres per minute. (34)   
To determine filtration efficiencies of N95 FFRs, Qian et al (35) calculated aerosol mass 
concentrations inside different companies’ N95 FFRs by doing measurements with particle-
size spectrometers, using bacteria with a similar size and shape to TB bacilli. They showed 
mean filtration efficiencies of more than 99.5%. Penetrated mass fraction is the term used 
to describe the aerosol mass that penetrated the filter as a fraction of the aerosol mass it 
was challenged with. When there is no leakage around the edges of the respirator, the 
penetrated mass fraction of the respirator is 0.02% for larger particles and 1.7% for particles 
smaller than a micrometre in diameter.  
Leaking around a poor face seal is the limiting factor when it comes to the protection 
offered by a FFR. The European Committee for Standardization requires that respiratory 
protective devices are tested for total inward leakage, a measure of how much ambient air 
leaks into the breathing zone between the skin and the FFR. This can be determined in a 
laboratory by using either aerosolised sodium chloride or sulphur hexafluoride. (36) 
The South African National Standard for FFRs (SANS 50149:2003) as set by the Council for 
Scientific and Industrial Research (CSIR) is an identical implementation of the European 
Standards of Disposable Respirators (EN149:2001 Ed2). (37-39) The EN 149 standard is 
deemed to be superior to the NIOSH standard, because it includes the criteria for total 
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inward leakage, fit and seal. FFRs are classified as filtering facepiece (FFP) 1, 2 or 3. FFP1 
reduces the wearer’s exposure to airborne particles by a factor of four and allows for 25% 
total inward leakage rate (refer to Table 1.2). In medical respiratory protection FFP2 
respirators are recommended. The NIOSH approved N95 FFR cannot be compared to 
EN149:2001 standards as the test requirements are very different. 
Table 1.2 European Standards of Disposable Respirators of EN149: 2001 (38, 39) 
Classification Protection 
factor  
Filter penetration limit 
(at 95L/min air flow) 
Inward 
leakage 
FFP1  4  Filters ≥ 80% of airborne 
particles 
<22% 
FFP2  10  Filters ≥ 94% of airborne 
particles 
<8% 
FFP3  20  Filters ≥ 99% if airborne 
particles 
<2% 
The face-seal, the self-fit check and the fit test procedures shall be discussed. 
1.5.1 The face-seal 
The FFR can only protect the user if it is properly selected, correctly donned, forms an 
impenetrable seal with the user’s face and worn all the time that the user is exposed to 
potential airborne hazards. Appropriate doffing technique and disposal or maintenance are 
essential. The idea behind fit testing is to identify that small percentage of individuals who 
will have an inadequate fit with the first respirator they try. (36) 
1.5.2 The self-fit check 
In the absence of the time consuming fit test, the self-fit check gives an indication of the 
quality of the seal, but it does not replace proper fit testing. Manganyi and Wilson (40) 
recommended that employees be trained to perform a daily self-fit check (or seal check).  
The following self-fit check is recommended by the manufacturer 3M™ in the technical 
datasheet of the 3M™ Aura™ N95 Respirators. (41) 
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  Cup both hands to cover the front of the FFR without disturbing the seal.  
  Forcibly exhale.  
  Readjust the nose clip to eliminate leakage around the nose.  
  Readjust the straps to eliminate leakage at the edges of the FFR. 
1.5.3  Fit testing procedures  
Fit testing follows a standard procedure to determine if a given model and size of FFR will fit 
the specific wearer and should be done with the same FFR that he/she will have access to in 
the field. (42) Qualitative or quantitative fit test methods are available. 
Qualitative fit testing relies on a subjective response from the user to the agent tested. If 
the user cannot detect or smell a standardised indicator odour or mist while breathing 
through the FFR it means two things: the specific FFR has the potential to provide a 
satisfactory face seal with his or her face and that the user can don the mask correctly.  The 
qualitative respirator fit test is affordable, uses simple equipment and is easily available 
from local dealers of personal protective equipment. (40) Clayton et al (36) make an 
important statement: “Passing a fit test does not guarantee that every time a wearer dons a 
facepiece an adequate fit will be achieved.”  
Quantitative fit tests objectively generate a fit factor number. This is mainly done for 
research and quality control purposes and requires expensive equipment like a 
condensation particle counting instrument (Portacount®) and a customised FFR fitted with a 
sampling probe connected to the particle counter with a sampling line. (43) Quantitative fit 
tests are superior to qualitative testing. 
How often a fit test should be done is a matter of great controversy in the literature at the 
moment. Canadian, American and Australian guidelines demand either annual or biannual 
fit testing. In the United Kingdom a second fit test is only required when the user changes to 
a different respirator model or if the user has undergone major changes to his or her facial 
characteristics. This may happen in cases of severe weight loss or gain and also in cases of 
dentition alterations or surgery. (36) 
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Fit testing is mandatory in the USA according to the American Standard ANSI Z88.2 of 1969. 
The mandatory fit testing protocols are set out in the subpart on personal protective 
equipment in the Occupational Safety & Health Administration (OSHA) Standard 1910.134 
Appendix A as published by the USA Department of Labor (44). A summary of the protocols 
will be discussed.  
Fit testing is not regulated in South Africa and the National Infection and Protection Control 
Policy and Strategy (45) does not specify a protocol for fit testing. However the CSIR does 
not perceive it to be merely an optional responsibility and recommends that fit testing 
should be done initially as the worker is allocated to a place with potential TB contact, and 
thereafter it should be repeated at least annually. (46) 
Fit testing procedures – general OSHA requirements 
Most, but not all, of the general requirements are described here. (44) Employees are asked 
not to eat, drink, smoke or chew gum for half an hour before testing, so as to not confuse 
the taste of the test solution. Drinking water is allowed. 
Guidance as to the proper technique of donning the FFR is given. A mirror should be 
available for self-observation. The employee selects a FFR from an adequate assortment of 
respirator styles and sizes. The FFR should fit comfortably on the employee’s face, with 
room for protective eyewear and room to talk. (44) 
OSHA criteria for acceptability of the FFR fit are: 
 Chin properly placed; 
 Adequate strap tension, not overly tightened; 
 Fit across nose bridge; 
 Respirator of proper size to span distance from nose to chin; 
 Tendency of respirator to slip; 
 Self-observation in mirror to evaluate fit and respirator position. (44) 
The test is abandoned if the employee has facial hair that would hinder the FFR from 
forming a seal with the skin. This also applies to any type of apparel that cannot be removed 
and interferes with an acceptable fit. (44) 
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Employees will be asked to do the following exercises for qualitative and quantitative fit 
tests. 
 Without talking, the employee breathes normally.  
 The employee breathes slowly and deeply, avoiding hyperventilation.  
 The employee slowly turns his/her head all the way from side to side. Inhale 
at each side.  
 The employee slowly moves his/her head up and down. Inhale when looking 
upwards.  
 The employee talks out loud. The subject can read from a text, or recite a 
poem.  
 The employee bends over at the waist as if touching his/her toes. This 
exercise can be substituted by jogging on the spot.  
 Normal breathing. (44) 
Dedicate 60 seconds per exercise. The fit test is abandoned if the employee adjusts the 
respirator fit during the test exercises. 
OSHA Qualitative fit test protocols 
Isoamyl acetate (banana oil) fit test protocol 
After screening for the employee’s ability to smell banana oil, a chosen FFR is donned. The 
exercises described above are performed in the test chamber filled with the vapour of the 
isoamyl acetate. The fit test is failed if the employee becomes aware of the banana odour. 
He/she should leave the room, remove the FFR and repeat the test with a different size or 
model FFR until the test is passed. (44) 
Saccharin and Denatonium Benzoate (Bitrex®) fit test protocol  
Firstly the employee’s ability to taste the test agent, which could be saccharin or Bitrex®, is 
screened for. The employee dons the fit test enclosure (a hood that fits over the head and 
shoulders) without wearing the FFR. The test conductor introduces a fine mist of diluted 
saccharin or diluted Bitrex® solution into the enclosure with a nebulizer. The nozzle of the 
nebulizer fits through a 1.9 cm hole facing the employee's breathing zone. The employee is 
asked to breathe with the mouth slightly open and the tongue extended. After 10 rapid 
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sprays the employee should try to detect the taste. More sprays may be introduced if 
needed. As soon as the employee reports tasting something, the screening test is 
completed. The employee may don the chosen FFR and proceed to the fit test.  
The fit test is done with the employee wearing the FFR correctly donned inside the 
enclosure. The undiluted test solution is aerosolized through the hole while the employee 
breathes as indicated. The employee is requested to perform the exercises mentioned 
under general requirements. If the employee reports detecting the test solution, the fit is 
deemed to be unacceptable. An alternative FFR should be fitted and the entire procedure 
repeated. The employee shall only remain unaware of any taste or smell, if the FFR fits 
perfectly with no face leak shall. 
Saccharin is a freely available artificial non-caloric sweetener approved in more than 100 
countries and also by regulatory agencies that include the USA Food and Drug 
Administration, the Joint Expert Committee on Food Additives of the WHO, Health Canada 
and the European Food Safety Authority. (47) 
Bitrex® is officially recognised in more than 40 countries as a safe “taste aversion agent” in 
domestic liquids to deter children from ingesting them. (48) It was approved in the United 
Kingdom and the USA in the early 1960s. (49) The bitter taste causes an almost involuntary 
reaction from the test subject, making false results unlikely. (44) 
Stannic chloride fit test protocol 
Smoke that is irritating to eyes and airways is used. (44) It is not discussed as other humane 
and environment friendly fit testing options are available. 
Quantitative fit test protocols 
Two quantitative fit test methods are available to test the seal of FFRs: Ambient test agent 
aerosol with a condensation nuclei counter, for example the Portacount® (most common 
method), or alternatively the controlled negative pressure FitTester 3000TM capable of 
determining the volumetric leak rate of the FFR (44). The equipment for these tests are 
expensive to come by and won’t be discussed further. 
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1.5.4  Design of FFRs 
Manufacturers design FFRs based on anthropometric data on facial characteristics and sizes 
obtained from large numbers of people grouped into “respirator fit test panels”. These 
panels were originally developed by the NIOSH based on data from the USA. (50, 51) Face 
length and width appear to be the most important measurements, but lip length and nasal 
width may also be relevant. Previous studies on respirator fit underrepresent the facial 
dimensions of females and non-Caucasians. (52)  Data on South African facial dimensions 
are limited and the FFRs manufactured for local use may not be applicable to the 
inhomogeneous characteristics of South African faces. (40)  
1.5.5  Sizes of FFRs 
The CSIR recommend that institutional bulk orders should reflect the normal distribution 
across small, medium and large sizes (20% small, 60% medium and 20% large) but it is more 
important to accommodate local demographics. (37) 
Spies et al (53) conducted a preliminary study on 29 South African volunteers from both 
genders and different races. The sample group’s anthropometric measurements 
represented a range of facial dimensions. Repeated quantitative fit testing was done with 
the volunteers wearing a medium size FFR from a commonly available brand. Facial 
dimensions of the males in the group were found to be fairly similar to those measured in 
Korea and America. (53) A satisfactory fit was achieved by 4 (13.8%) participants. The large 
percentage that failed the fit test leads to the conclusion that more than one respirator 
model and/or shape should be available. “One size does not fit all.”  
1.6 FFR use 
1.6.1  FFR performance and face fitting characteristics 
FFR performance has been studied extensively in laboratory settings, but it is not clear how 
the research translates to a precise level of HCW protection. (27, 54) This may be the reason 
why some HCWs elect not to use FFRs at all, despite working in potentially contaminated 
environments.  
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Coffey et al (43) evaluated on behalf of the NIOSH the performance of 18 N95 respirator 
models available in 1998 with five different fit tests including both qualitative and 
quantitative tests. The second component of the evaluation was to determine whether fit 
testing had an effect on the level of protection. Level of protection was evaluated and rank-
ordered by four different measures of protection. Twenty-five people with different facial 
dimensions participated. It was found that passing the fit test positively correlates with an 
increased level of protection.  
1.6.2  HCW knowledge, attitudes and use of FFR 
Manganyi et al (40) state that there is poor understanding of the proper use of FFRs and fit 
testing in South Africa. HCWs are hardly ever trained on how FFRs are supposed to fit, how 
they should be donned and worn and what their shortcomings are. Most don’t know that 
there are different sizes and styles of FFRs available, nor are they aware that facial hair 
renders the face seal ineffective. South African employers are still of the erroneous opinion 
that one size of FFR will fit all employees. 
Adeleke (22) collected data from focus group discussions and semi-structured interviews 
with HCWs from two clinics in Khayelitsha. It was found that despite dreading nosocomial 
TB, HCWs sometimes neglected personal protective equipment, because of discomfort, 
feeling smothered and difficulty in breathing associated with wearing the FFR.   Importantly 
it was found that HCWs use personal protective equipment in a reactive fashion, an FFR 
would only be donned once TB has been diagnosed. This shows that there is poor 
understanding of the potential risk posed by undiagnosed and untreated TB cases and 
indicates the importance for education on proactive FFR use. Other complaints that the staff 
highlighted are that it feels hot, it is a communication barrier, proper donning and doffing 
take a long time and it chokes them.  
Bhebhe et al (55) performed a cross-sectional descriptive study at the Maluti Adventist 
Hospital in Lesotho in 2011. Seven HCW were diagnosed with healthcare-associated TB in 
2009 in this hospital. Of the 129 respondents, 115 (89.2%) demonstrated adequate 
knowledge of transmission and prevention of TB. Despite the adequate knowledge only 
38.8% of the respondents stated that they use the N-95 respirator. Forty seven of the 
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participants (36.4%) reported that they were aware that their personal TB infection control 
practices were incorrect. (55)  
Biscotto et al (56) randomly observed 145 HCWs in a Brazilian hospital between December 
2000 and March 2001. Of the HCWs who partook in the study 59.3% were nurses and 30.3% 
were doctors and 10.3% other.  Only 25% of HCWs used respirators for intubation. For 
encounters with patients in TB isolation respirators were worn for only 39.5% of encounters. 
Facial leakage was observed in 39% of HCWs who actually did wear the FFR, even though all 
users received training and fit testing at the beginning of the trial period. The most common 
cause of leakage was improper placement or tension of the straps. The FFRs themselves 
were observed, 90.3% were dirty, 19.4% were crushed or torn and 1.1% were moist. (56) 
The limitations of this direct observation study are that HCWs were aware of the study and 
their behaviour may have been influenced by the presence of the study personal over the 
defined time period.  
Bryce et al (54) analysed 137 questionnaires distributed among HCWs in Vancouver Canada 
in a facility that uses airborne precautions when confronted with “patients with a new onset 
respiratory illness”. TB ward staff were excluded. More than 95% of participants had a fit 
test at least once in their career and about 60% reported annual fit testing.  
Compliance with FFR guidelines was examined by means of a six-point Likert scale from 0 - 
5. The range of the “compliance score” was 0 - 25 and the mean score was 21.2 (SD: 2.9). 
(54) 
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The five statements concerning compliance were: 
 I wear an N95 respirator when there is the possibility of an infectious airborne 
disease 
 I perform a fit check after putting on my N95 respirator 
 I clean my hands before removing my N95 respirator 
 I discard my N95 respirator immediately after use 
 I take my N95 respirator off after I leave the room. (54) 
The results show that despite regular training and well established airborne precaution 
practices at the hospital, some employees still do not understand or have a negative 
attitude towards fit testing and compliance with infection control precautions. In poor 
resource environments in the developing world the problem is compounded by a higher 
incidence of TB, insufficient training and restricted access to FFRs. 
The same questionnaire also generated a “comfort-score” by asking participants to compare 
the FFR with a surgical mask on a Likert scale from 1 - 5 on four statements concerning 
comfort: (54)  
 The N95 respirator is comfortable 
 The N95 respirator does not make me short of breath 
 The N95 respirator does not make me claustrophobic 
 The N95 respirator does not make me feel dizzy. (54) 
No FFR was found to be more comfortable than the other. The “global comfort score” was 
13.6/20. (54) 
1.6.3  Guidance and recommendations on infection control 
The recommended CDC guidelines, the National Institute for Health and Care Excellence 
guidelines and South African National Infection Prevention and Control Policy and Strategy, 
as well as protocol for infection control at CMJAH are briefly discussed. 
Personal respiratory protection is recommended by the CDC, especially in settings where 
exposure controls are inadequate. A comprehensive respiratory protection program should 
be implemented featuring aspects such as the assigning of a responsible administrator, 
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training of HCWs on the hazards and prevention of TB transmission and FFR selection with 
periodical FFR fit testing. (27) 
The updated National Institute for Health and Care Excellence guidelines from January 2016 
recommend tuberculin skin test (TST) programmes for at-risk staff.  A positive TST warrants 
treatment with isoniazid for 6 - 9 months to prevent progression to active disease. (57) 
Bacillus Calmette–Guérin (BCG) immunisation can lead to incorrect interpretation of the TST 
result. 
The South African National Infection Prevention and Control Policy and Strategy from April 
2007 declares that too few HCWs have formal training in infection control. (45) All HCWs 
need to be made aware of the significance of “prevention, surveillance and control of 
infections amongst HCWs.” 
The Infection Prevention & Control Protocol Isolation Precautions at the Charlotte Maxeke 
Johannesburg Academic Hospital in Gauteng were due for revision in August 2015, however 
are still unavailable. Currently the guidelines state that in the case of pulmonary TB, chicken 
pox, shingles and measles the following airborne precautions should be followed: 
The patient is placed in a private ward/ cubicle. The door must be kept closed. A 
mask and apron/gown are put on when entering the room. In the case of MDR/XDR 
TB N95 respirators must be collected from Infection Prevention and Control Area 
421. If the patient has to be transported to other areas, the patient must wear a 
surgical mask. (58) 
The suboptimal implementation of infection control guidelines requires an urgent 
transformation in workplace behaviour. Infection control practices will only be sustained 
when HCWs have insight into the risk of occupational TB and receive in-service training on 
TB infection control practices. (22) As emphasised by Whitelaw (59), the financial 
considerations of FFRs are but one of the difficulties of its use in South Africa, the others 
being discomfort, the lack of fit testing and the lack of adequate training. 
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1.7 TB and the anaesthetist 
1.7.1  Undiagnosed patients 
Anaesthetists have contact with infectious patients coming for surgery, especially when 
there is a delayed diagnosis and treatment initiation.  
1.7.2  High risk procedures 
Anaesthetists are closely involved in high risk procedures that induce coughing such as 
intubation, ventilation, bronchoscopy and suctioning of the airways. Catanzaro (60) alleged 
in 1982 that mainly bronchoscopy and intubation were predominant risk factors for 
occupational TB transmission. This was based on the finding that 10 out of 13 HCWs present 
at the bronchoscopy of an infectious patient, subsequently converted to TST positive. High 
exposure situations according to TB guidelines by Chughtai et al (61) include “Exposure to 
drug resistant organism; culture/DST [Drug Susceptibility Testing], and other high risk 
procedures in laboratory; high risk areas; specialised treatment centres and emergency 
surgery of infectious cases.” 
1.7.3  Administrative and environmental control inadequate in operating theatre 
Both administrative and environmental transmission control measures are almost 
impossible to achieve in operating theatres. Instead of open windows and doors to provide 
a natural ventilation system and sunlight, theatres are windowless and doors remain closed. 
To compound the problem operating rooms are positively pressurised with air vents close to 
the floor. (62) The positive pressure in theatre tends to disperse the infectious droplet 
nuclei. Prolonged exposure to the suspended tubercle bacilli in the closed environment of 
an operating room creates optimal circumstances for transmission. Isolation of the patient is 
administratively problematic during transport, in the pre-operative area, or recovery room. 
Infectious patients enter and leave through the same central areas as everyone else. 
Therefore the anaesthetist is at a significant risk of acquiring TB at work.  
In 2005 the CDC recommended that ultraviolet germicidal irradiation (UVGI) supplement 
existing TB transmission control programs in hospitals. UVGI is an environmental control 
measure of air disinfection. (26) Nardell et al (63) makes a case for upper-room UVGI in 
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bronchoscopy procedure rooms. These UVGI lamps predominantly emit ultraviolet C light, 
with a wavelength around 253.7nm, as this wavelength is mostly absorbed by the superficial 
layers of the skin and cornea, thus theoretically causing less skin cancer and cataracts than 
ultraviolet A and B light. (64) The high position of the UVGI ensures that radiation exposure 
to the occupants in the room is minimized. Research done by Escombe et al (25) in Lima, 
Peru showed that upper-room UVGI are an effective intervention in reducing TB 
transmission. The safety of UVGI in the operating theatre where there are many reflective 
surfaces has not yet been established.  
1.7.4 Guidance on the perioperative management of the patient with active TB  
The CDC 2005 guidelines on the perioperative management of patients with active TB have 
not yet been updated and advise that elective surgery be avoided until the patient has been 
on treatment for two to three weeks, is clinically improving, and has laboratory evidence of 
three negative sputum samples on three different days. Elective cases should be scheduled 
as the last case on the list to maximise time for comprehensive decontamination after 
hours. (27) 
The patient should be transferred to theatre wearing a surgical mask. (27) Dharmadhikari et 
al (65) published research done at the Airborne Infections Research Facility in eMalaheni, 
previously called Witbank. Guinea pigs were used because they are very susceptible to TB 
transmission. Exhaust air was piped from a specialised MDR-TB ward to the enclosure of the 
guinea pigs for three months. When the patients in the ward wore surgical masks for 80% of 
the time a 56% decrease in TB transmission to the guinea pigs was shown.  Hui et al (66) 
used a human patient simulator to show that neither a surgical mask nor a FFR can prevent 
sideway leakage when challenged with the force and volume of a cough. Both reduced the 
expelled air dispersion significantly from an uncovered cough, thereby protecting the 
environment by keeping infectious droplets in the immediate vicinity of the patient. It was 
concluded that the extra discomfort and cost associated with the FFR do not add any benefit 
in protecting the environment from the cough of the wearer. 
The patient should be transported straight to theatre and not to the common pre-operative 
waiting area. Only the necessary staff should be present in theatre to minimise the number 
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of HCWs exposed. Everyone present in theatre should wear an appropriate, well-fitting FFR. 
During intubation the anaesthetist should ensure sufficient hypnosis and muscle relaxation 
to prevent coughing. (67) 
Air cleaning technology such as UVGI and high-efficiency particulate air filters may be 
implemented in theatre to reduce the quantity and concentration of airborne infectious 
droplets. Installation and maintenance of this technology is expensive. Bacterial filters 
should be used in the breathing circuit, both at the patient end and at the expiratory limb to 
protect the anaesthetic machine from contamination. Pleated hydrophobic filters do not 
allow M bovis (a test surrogate for M tuberculosis) to penetrate. (68)  Jackson et al (67) 
advocate sterilisation of the used breathing circuit, but if resources allow it would be 
prudent to safely dispose of it. The patient should be recovered in either theatre, or an 
isolation room in the ward. 
1.8 Summary 
In South Africa the high incidence of TB poses a considerable occupational health risk to 
HCWs. A comprehensive respiratory protection program consists of administrative, 
environmental and personal protection measures. HCWs who have access to the 
recommended personal respiratory protection are still at risk of TB transmission when there 
is a face leak between the FFR and the skin. An inappropriately fitted or sized FFR may give 
the HCW a false sense of protection. Compliance with infection control guidelines is 
universally insufficient. Due to the nature and environment of their occupation, 
anaesthetists are a vulnerable group of HCWs due to their proximity to patients with 
potentially undiagnosed TB and high risk procedures. 
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Section 2: Author’s Guidelines 
This article will be submitted to the Infection Control & Hospital Epidemiology (ICHE) journal 
in the category “original article”. Below are the author’s guidelines copied from the ICHE 
website under the “ICHE Instructions for Contributors” link, also available at 
http://journals.cambridge.org/action/displaySpecialPage?pageId=7876. 
Last updated August 27, 2014 
Infection Control & Hospital Epidemiology 
Published for The Society for Healthcare Epidemiology of America in partnership with 
Cambridge University Press 
Instructions for Authors 
GENERAL INFORMATION 
Manuscripts submitted to Infection Control & Hospital Epidemiology (ICHE) should consist of 
original investigations that will contribute to the fields of healthcare epidemiology and 
infection prevention with the ultimate goal of improving healthcare safety. ICHE welcomes 
submissions that address the transmission of pathogens or that involve the use of 
epidemiological principles and methods to evaluate or improve the delivery of care within 
healthcare institutions. Examples of appropriate material include studies of infection 
surveillance, the impact of preventive measures on infection rates; analyses of resource use 
and costs related to infections or other adverse events in patients; occupational health; or 
pertinent regulatory issues. Authors are responsible for ensuring that manuscripts adhere to 
the formats noted in the Instructions for Authors. Articles should be submitted 
electronically at the journal’s submission website, at http://iche.edmgr.com. 
ARTICLE TYPES 
Original Articles should include a title page, a structured abstract of no more than 250 
words (see below), a text of no more than 3,000 words, no more than 7 tables and figures, 
and no more than 40 references. 
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Concise Communications should include a title page, a narrative abstract of no more than 50 
words, a text of no more than 1,200 words, no more than 2 tables or figures, and no more 
than 10 references. 
Research Briefs should include a title page, a text of no more than 900 words, no more than 
1 table or figure, and no more than 10 references. This category of article is intended for the 
presentation of short, focused, and evidence-based experimental observations: substantial 
preliminary and novel results of importance to the journal readership but not substantial 
enough in content to warrant a longer presentation. Research Briefs undergo the same peer 
review as longer article types. 
Letters to the Editor should not exceed 900 words and should include no more than 1 table 
or figure and no more than 10 references. 
Invited Reviews, including guidelines and position papers: committees, task forces, and 
authors under the auspices of the Society for Healthcare Epidemiology of America, and all 
others considering the preparation of a review, should contact the Editorial Office during 
the very earliest phases of development. The Editor-in-Chief will verify that there are no 
similar or overlapping documents under development. Anticipated length, format, number 
of citations, and mechanisms for peer review and publication by ICHE and the involvement 
of any other organizations will be negotiated with the journal and publisher well in advance 
of submission. 
Commentaries are by invitation only. Please contact the journal office if you are interested 
in writing a Commentary. 
MANUSCRIPT PREPARATION 
Authors are encouraged to follow the Uniform Requirements for Manuscripts Submitted to 
Biomedical Journals; this is the format used in PubMed/MEDLINE. They should strive for a 
concise article that is unencumbered by excessive detail. Authors who are not fluent in 
English should have their manuscript checked by a native speaker of English and/or an 
editing service that provides such assistance. Manuscripts that do not follow the required 
format or are poorly prepared may be rejected for that reason. 
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For guidance regarding the reporting of randomized (CONSORT), observational (STROBE), 
meta-analyses (PRISMA), and other clinical trials, please consult www.equator-network.org. 
Double space the entire manuscript, including title page, abstract, body, references, tables, 
and figure legends. Use left justification only, so that the right margin is ragged. Number 
pages consecutively, beginning with the title page. Use a standard font (such as Times New 
Roman or Helvetica) and set the font size to 12 points (for tables as well as text). Each 
component of the article should begin on a separate page, as follows: title page, abstract, 
body text, acknowledgments, references, appendices, figure legends, and tables. All these 
components must be in a single file, except any figures, each of which should be a separate 
file (see Figures and Figure Legends, below). 
Title Page 
The title page should include the following information: (1) the title of the manuscript; (2)  
the names of the author(s), including each author’s highest academic degree or professional 
certification; (3) the departmental and institutional affiliation of each author, including city, 
state, and country; (4) the name, address, telephone number, fax number, and e-mail 
address of the author responsible for correspondence, and (if different) the name and 
address to be used for reprint requests; (5) if relevant, a statement about any previous 
presentation of the data or findings in a preliminary report or abstract; (6) an abbreviated 
title of not more than 45 characters (including spaces), to be used as a running head in print 
and for search results online; and (7) a word count for the body of the text (i.e., excluding 
the abstract and the references). 
Acknowledgment of financial support and potential conflicts of interest must be included 
and should be placed in the Acknowledgments section (see below). 
Abbreviations should conform to those given in the AMA Manual of Style. Symbols for units 
of measurement (mm, mL) should not be followed by periods. Chemical or generic names of 
drugs, materials, and equipment are strongly preferred; a proprietary name may be given 
only after it is preceded by the generic or chemical name the first time it appears and must 
be followed by the name of the manufacturer or supplier. Terms and abbreviations must be 
defined at first use, separately for the abstract, the body, and each table and figure. Use 
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only common abbreviations and use as few as possible; and do not abbreviate terms used 
fewer than 5 times. Abbreviate genus names after first mention. 
Abstract 
Original Articles should include a structured abstract of no more than 250 words. The 
following headings are suggested: Objective, Design, Setting, Patients (or Participants), 
Methods (or Interventions), Results, and Conclusions. If this list of headings is inappropriate, 
variations are permitted: for example, a study that involved no intervention would use the 
heading "Methods" rather than "Intervention"; or an analysis of an existing data set might 
use the heading "Methods" in place of both "Intervention" and "Setting." For brevity, parts 
of the abstract can be written in phrases rather than complete sentences, .e.g., “Design: 
Retrospective cohort study". The contents of each section should conform to the guidelines 
below. 
Objective. Begin with a clear statement of the precise objective or question addressed in 
the report. If more than one objective is addressed, indicate the main objective and state 
only key secondary objectives. If an a priori hypothesis was tested, it should be stated. 
Design. Describe the basic design of the study. Include the duration of follow-up, if any. Use 
as many of the following terms as apply. 
• For intervention studies: randomized controlled trial; nonrandomized controlled trial; 
double-blind; placebo controlled; crossover trial; before-after trial. 
• For studies of screening and diagnostic tests: indicate the criterion standard against which 
a new or alternative test is being compared; blinded or masked comparison. 
• For studies of prognosis: inception cohort (subjects assembled at a similar and early time 
in the course of the disorder and followed thereafter); cohort (subjects followed forward in 
time, but not necessarily from a common starting point); validation cohort or validation 
sample, if the study involves the modelling of clinical predictions. 
• For studies of causation: randomized controlled trial; cohort; case-control; survey 
(preferred to "cross-sectional study"). 
• For descriptions of the clinical features of medical disorders: survey; case series. 
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• For studies that include a formal economic evaluation: cost-effectiveness analysis; cost-
utility analysis; cost-benefit analysis. For new analyses of existing data sets, the data set 
should be named and the basic study design disclosed. 
Setting. To assist readers in determining the applicability of the report to their own clinical 
circumstances, include a brief description of the study setting(s) such as: primary or tertiary 
referral center, private or public institution, or an ambulatory or acute care setting. 
Patients or participants. Provide information on important eligibility criteria, and key 
sociodemographic features of patients and how they were selected, including the number of 
otherwise eligible subjects who were approached but refused to participate. If matching 
was used for comparison groups, specify the characteristics that were matched. In follow-up 
studies, the proportion of participants who completed the study must be indicated. In 
intervention studies, the number of patients withdrawn because of adverse effects should 
be given. 
For selection procedures, these terms should be used, if appropriate: random sample 
("random" refers to a formal, randomized selection in which all eligible subjects have a fixed 
and usually equal chance of selection); population-based sample; referred sample; 
consecutive sample; volunteer sample; convenience sample. 
Intervention(s). Describe the essential features of any interventions, including the method 
and duration of administration. The intervention should be named by its most common 
clinical name (e.g., the generic term "oseltamivir"), the brand name of a drug, if a specific 
product was studied, and the name of the manufacturer or supplier for any product(s) 
mentioned in the manuscript, including software. 
Results. Give the main results of the study in narrative form. Define measurements that 
require explanation for the expected audience of the manuscript. If possible, the results 
should be accompanied by objective data and the exact level of statistical significance. For 
comparative studies, confidence intervals should relate to the differences between groups. 
When risk changes or effect sizes are given, indicate absolute values, so that the reader can 
determine the absolute, as well as relative, impact of the finding. Approaches such as 
"number needed to treat" to achieve a unit of benefit are encouraged when appropriate. 
Studies of screening and diagnostic tests should use the terms sensitivity, specificity, and 
35 
 
likelihood ratio. If predictive values or accuracy are given, prevalence or pretest likelihood 
should be given as well. 
Conclusions. Only those conclusions of the study that are directly supported by the evidence 
reported should be given, along with the clinical application; indicate whether additional 
study is required before the information should be used in normal clinical settings. Equal 
emphasis must be given to positive and negative findings of equal scientific merit. 
Clinical trials identifier. If your manuscript is the report of a randomized clinical trial that 
has been registered in a public trials registry, please provide the trial registry name, the 
registration identification number, and the URL for the registry at the end of the abstract. 
This information will be published in the journal if the manuscript is accepted. 
Body Text 
The main sections and subdivisions of the body text should be indicated by side heads flush 
with the left margin and two lines above the text. 
Keep Introduction, Methods, Results, and Discussion distinct and separate. The Methods 
section should provide detail sufficient to allow others to re-create your experiment. 
Methods may not be described or restated in figure legends or table notes, but must be all 
together in the Methods section. The Results section contains the previously unpublished 
data derived by this application of your methods. The Discussion section contains your 
interpretation of the reported data and comments on its meaning. There should be no 
separate section labelled "Conclusion." Avoid duplicating in the text data that have been 
provided in tables or figures. Also avoid duplication within the text; the Discussion section 
should not restate all the findings that have been presented in Results and/or in tables and 
figures.  
The Editor requests that authors reporting the results of clinical trials describe clearly the 
following: (1) eligibility criteria; (2) whether subjects were admitted before allocation to one 
of the study groups; (3) the method of randomization; (4) whether the study was "masked," 
what specific information was masked, and whether subjects, clinicians, and evaluators 
were masked; (5) the method used to identify treatment complications; (6) an explanation 
and analysis of subjects lost to follow-up; (7) statistical methods used; and (8) information 
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that led to the determination of the size of the study groups and the expected differences 
between groups. For all studies involving human subjects, the Methods section should 
include a statement that the study was reviewed and approved by the authors' institutional 
review board.  
Footnotes are acceptable in tables but cannot be used in the body of the manuscript; any 
footnotes in your manuscript will be integrated into the text, perhaps in parentheses. 
  
37 
 
Acknowledgments 
Financial support. The Acknowledgments section should list all sources of financial support 
or the work, including any financial arrangement with a company whose product is related 
to the study. If there was no financial support, that too should be stated. The statement 
should be consistent with disclosures that would be stated in the ICMJE Form for Disclosure 
of Potential Conflicts of Interest. 
Examples: 
• Financial support. The GERES Project is supported by the French Ministry of Health. 
Additional support for this study was provided by Becton-Dickinson and SIMS France. 
• Financial support. H.S.C. received grant support from the Department of Veterans Affairs 
Rehabilitation Research and Development Service Merit Review (C2234-MD and C3- 
2442MD), D.B.L. received support from the US Public Health Service (grant HC41024), and 
A.E.T. received salary support from an Emerging Infectious Diseases Cooperative 
Agreement. C.U. receives 2% salary support from Aventis Pasteur for work on another 
study. 
• Financial support. None reported. 
Conflict of interest. The Acknowledgments section must contain a statement of potential 
conflicts of interest. If the manuscript is accepted for publication, the disclosures will be 
published. The Acknowledgments section of the manuscript must list the name of each 
contributing author and any potential conflicts of interest for each author for the previous 
three years; if no potential conflict exists, that too should be stated. The statement should 
be consistent with disclosures that would be stated in the ICMJE Disclosure Form. There is a 
potential conflict of interest when anyone involved in the publication process has a financial 
or other beneficial interest in the products or concepts mentioned in a submitted 
manuscript, or in competing products, that might bias his or her judgment. Examples of 
potential conflicts of interest with respect to a company whose product is mentioned in the 
manuscript include owning stock (except as part of a diversified portfolio), receiving grants, 
serving as a consultant, or being on the speakers' bureau. (This information is exclusive of 
the financial support discussed above.) 
38 
 
Examples: 
• Potential conflicts of interest. S.A. and K.H. report that they are shareholders in Loke 
Diagnostics (Aarhus, Denmark). 
• Potential conflicts of interest. K.L.H. reports having consulted for and having received grant 
support from Astellas and reports having received an honorarium from Cubist before 
starting employment with the New York Department of Public Health in 2009. 
• Potential conflicts of interest. E.F.M. reports that she has been a consultant to Merck, 
Novartis, and GlaxoSmithKline and is member of the speakers' bureaus for Ortho McNeil 
and Novartis. 
J.A.S. reports that he received research funding from Bayer and Ortho McNeil and that he 
has been a consultant for Bayer and Pfizer. J.D.C. reports that he is an employee of AB 
Biodisk. 
• Potential conflicts of interest. All authors report no conflicts of interest relevant to this 
article. 
Authorship and manuscript preparation. If the manufacturer of a product discussed in a 
submitted manuscript had a role, either directly or through a third party, in the gathering or 
preparation of data or in the writing of the manuscript, that information must be disclosed 
in the Acknowledgments section. If anyone other than the named authors had a role in the 
gathering or preparation of data or in the writing of the manuscript, that too should be 
disclosed. 
Examples: 
• Manuscript preparation. Steris Corporation provided assistance with study design and 
data acquisition. 
• Manuscript preparation. Statistical and other analyses were done by 3M Medical Division. 
• Manuscript preparation. MedCommunications (Philadelphia) provided assistance in 
preparing and editing the manuscript. 
Disclosure documentation. All authors of Original Articles, Concise Communications, and 
Research Briefs are required to complete and upload the ICMJE Form for Disclosure of 
39 
 
Potential Conflicts of Interest when and if they are asked to submit a revision of their 
manuscript. All authors of Letters and invited manuscripts (Letters in Reply, Commentaries, 
Reviews, and Guidelines) are required to complete and upload the ICMJE Disclosure Form 
when they initially submit their manuscript. Note that this documentation is in addition to 
the disclosure statements in the Acknowledgments section of the manuscript file. 
Thank you notes. Persons should not be thanked in the Acknowledgments section without 
their knowledge and consent. Authors will be asked during the submission process to 
confirm they obtained permission from all persons thanked by name in the 
Acknowledgments section. 
REFERENCES 
References should be cited consecutively in the text, with superscript numbers placed 
outside periods and commas and inside colons and semicolons. References cited only in 
tables or figure legends should be numbered as though all were cited at the point at which 
the table or figure was first mentioned. 
A paper that is "in press" may be included in the reference list if it has been accepted for 
publication. Citations such as "in preparation," "submitted for publication," "unpublished 
data," and "personal communication" should be given in parentheses in the text only, 
including the names of all individuals to whom the information should be attributed, as well 
as each person's highest academic degree and the month and year of the information's 
origin. For personal communications, specify whether the communication was written or 
oral. 
At the end of each manuscript, list the references in numerical order, double spaced, 
according to the order they are cited in the text. If there are 7 or more authors, list the first 
3 authors' names, followed by "et al"; otherwise, list all authors. Abbreviations of journal 
names should conform to Index Medicus or MEDLINE. Unlisted journals should not be 
abbreviated. Authors are responsible for bibliographic accuracy. Journal titles should be 
cited as they existed at the time of publication. Format references according to the style 
given in the AMA Manual of Style, 10th Edition. 
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2. Camins BC, Richmond AM, Dyer KL, et al. A crossover intervention trial evaluating the 
efficacy of a chlorhexidine-impregnated sponge in reducing catheter-related bloodstream 
infections among patients undergoing hemodialysis. Infect Control Hosp Epidemiol 
2010;31:1118-1123. 
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3. Figueroa P, Johanssen KL, Price FG, et al. Outbreak of Acinetobacter infection in a 
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TABLES 
Prepare tables with the MS Word table editor; text formatted to look like a table by use of 
tabs and hard returns is not acceptable and will be rejected. Include tables in the same file 
as the rest of the manuscript, not in separate files. Tables should be double spaced. Number 
tables in the order in which they are cited in the text, and provide a descriptive title for each 
table.  
Every column in a table requires a head that describes the contents of the cells below. The 
units of measure for all data must be clearly stated in the heads, in the stub (leftmost) 
column, or in data cells, as appropriate. Do not use vertical lines, and do not use ditto marks 
for repeated information. 
List and define any abbreviations in a note below the table, above the table footnotes (no 
footnote designator is required for this line), even if the abbreviations have been defined in 
the text. Use superscript letters for footnote designators. 
Tables that are too large to be reproduced in print, if accepted for publication, will appear 
only in the online version of the article, and information about the online-only table 
(including a full or partial title) will be included in the print version of the article. 
Figures and Figure Legends 
Figures. Number figures in the order in which they are mentioned in the text, and provide a 
brief but descriptive caption (legend) for each figure. The journal does not print color 
figures. Color figures that can be usefully published in black and white will be published that 
way in print, and color versions will appear in the online journal if necessary. Figures that 
are useful only in color will be available only in the online version of the article, and 
information about the online-only figure (including a full or partial legend) will be included 
in the print version of the article. 
All artwork (figures, photographs, and illustrations) should be submitted as digital files. The 
required format is TIFF or EPS, with the following resolutions: 1,200 dpi for line figures (eg, 
graphs), 600 dpi for grayscale figures (eg, photographs), and 300 dpi for color figures. 
PowerPoint, Word, and JPEG files will not be accepted. Each figure or illustration must be a 
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stand-alone file, separate from the text file, and named to match the number cited in the 
text (eg, fig1.eps). Do not include titles and legends in illustration files. 
Figure legends should be double spaced on a separate page of the manuscript. (This is 
because a figure is reproduced as an image file, whereas the legend that accompanies the 
figure is typeset as text.) Place figure titles and explanations in the legend, not on the figure 
image. On the other hand, graphic elements that require definition, such as symbols, are 
best placed and defined in available open space within the figure itself. 
The text of the figure legend should concisely and accurately label what the figure depicts 
and define any abbreviations or terms used within it. The figure legend should not describe 
or restate methods, nor state or restate detailed findings, nor state a claim or conclusion 
drawn from the data displayed. Such statements belong in the appropriate section of the 
body text, not in a figure legend. 
Supplemental Material (Online-Only Material) 
An increasingly appealing option for journal authors is the inclusion of Supplementary 
Material with the traditional manuscript text. Supplementary Material is defined as any 
content that supports, but is not key to, the understanding of a print- and / or online-
published item’s message. Given that Supplementary Material is exclusively published 
online, it may include file types that are incompatible with a print format, eg., color versions 
of black and white figures, videos, audio, and Excel files containing interactive elements. 
Designation of content as “onlineonly” should not be used to shorten the anticipated print 
version of a submission. 
Supplementary Material is subject to the peer review process and copyright requirements 
as all primary content. Supplementary Material will be available on the Cambridge Website 
after approval by the Editor-in-Chief. 
The author is solely responsible for the content of this material. Supplementary Material will 
be made available only in its original format and will not be subject to copy editing, or 
typesetting. 
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As the submission of Supplementary files becomes more prevalent we would like to offer 
some guidelines for submission of Supplementary files to Cambridge University Press 
journals production. 
Most common types of Supplementary Material 
Common types of Supplementary Material include audio and video files and large datasets 
or tables. Datasets, tables, and other textual material are commonly submitted as PDF, 
Excel, or Word files. Our recommendations for the various types of files can be found in 
Appendix 1 at the end of this document. 
For each video, provide a citation in the appropriate place in the manuscript text and 
include a title and pertinent copy, preferably limited to 20 words. This citation will appear in 
print as a boxed text and also specify the video file format. In the case of multiple video 
files, number them in the order in which they should be viewed. If associated with a figure, 
please include a citation at the end of the figure caption explaining the video’s function, its 
file format, and that it is accessible at Cambridge’s CJO site: 
journals.cambridge.org. 
The video will be posted at the site of the appropriate journal title, volume, issue number, 
and article. At the article entry for the online table of contents the video can be accessed via 
a link which states “Supplemental Materials.” 
Please be advised that Cambridge University Press will not edit your video file. It will be 
posted online exactly as supplied. If deemed unacceptable, the author will be responsible 
for rectifying the problem and supplying an acceptable file. 
APPENDIX: Supplemental file submission requirements Accepted formats: pdf, doc/docx, 
xls/xlsx, ppt/pptx, jpeg, tiff, png, and zip  
Other acceptable file formats 
Audio Files 
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Video Files 
Video files should be submitted according to the following specifications. 
 
 
 
 
 
SUPPORTING DOCUMENTS 
Include a cover letter with your submission; the cover letter should state that all authors 
have read and approved the submission of the manuscript. The letter also should state that 
the manuscript has not been published elsewhere and that it is not currently under 
consideration for publication by another journal. Include the names and contact information 
for any individuals who are especially qualified to review the manuscript; you may also 
name any individuals who may not be able to provide an unbiased review. 
Any closely related manuscripts that have not yet been published should be included with 
the manuscript being submitted; ICHE does not publish articles that overlap substantially 
with work published or in press elsewhere. 
REVIEW AND PUBLICATION PROCESS 
Each manuscript is evaluated by two editors; most are sent to two outside reviewers. 
Authors are notified as soon as possible regarding the acceptability of their manuscripts. 
Note that acceptability may sometimes hinge on whether the manuscript is within the scope 
of the journal, the originality and quality of the study, and appropriateness and utility for 
our readership. Authors of accepted manuscripts are asked to sign a publication agreement, 
transferring copyright to the Society for Healthcare Epidemiology of America. Material 
published in the journal may not be reproduced or published elsewhere without written 
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Abstract 
Background: Reliable protection against nosocomial tuberculosis transmission in theatre 
depends on the appropriate use of filtering facepiece respirators (FFRs) with an N95 filter, as 
recommended by the Centers for Disease Control and Prevention.  
Aim: To describe anaesthetist compliance and comfort with the use of FFRs, followed by 
donning technique and fit tests outcomes. 
Design: Prospective, contextual, descriptive, two part study.  
Setting: Part 1 was done in a university affiliated department of anaesthesiology. Part 2 was a 
pilot study in the theatre complex of a 1200-bed tertiary-level academic hospital. 
Participants: Part 1 – anaesthetists in the department selected by convenience sampling 
(n=140). Part 2 – anaesthetists selected by stratified random sampling (10 male and 10 
female).  
Methods: In Part 1 a self-administered questionnaire was distributed. In Part 2 the donning 
technique was directly observed, corrected, then followed by qualitative fit testing with the 
single model and size FFR available. 
Results: Part 1 -Compliance with the use of the FFR was inadequate with a compliance score 
of 14.5 (SD 5.0) out of 25. FFRs are deemed to be uncomfortable (discomfort score of 9.9 
(SD 4.0) out of 21.) Part 2 - Of the 20 anaesthetists, six (30%), five males and one female, 
passed the fit test. 
Conclusions: Compliance with FFR use was poor and anaesthetists at the research institution 
found the FFRs uncomfortable. FFR donning technique was observed to be lacking. Research 
with a larger study group is required. Poor fit test results were most likely due to the 
availability of only one size and model of FFR. 
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Introduction 
“Tuberculosis (TB) remains a global health problem”.1 The estimated prevalence in South 
Africa is 696 cases per 100 000 compared to the global average of 133 cases per 100 000.1 
HIV and TB are symbiotic co-epidemics.2, 3 Approximately 10% of patients newly diagnosed 
with HIV have undiagnosed TB.4 The emergence of multi-drug resistant and extensively 
drug-resistant TB endangers the public and especially healthcare workers (HCWs). 4-6 In 
2009 the overall prevalence of TB among South African HCWs was about 5%.7 
 
Prevention of transmission of nosocomial TB requires three measures of control.8, 9 Firstly 
administrative measures which include early diagnosis, isolation and treatment. Secondly 
environmental measures including provision of natural or mechanical ventilation systems, 
extractor turbines, sunlight or ultraviolet irradiation, high-efficiency particulate air filters on 
exhaust air outlets and negative air ionization.10 Both administrative and environmental 
controls are almost impossible to achieve in operating theatres. The third measure of control 
is personal respiratory protection devices.11 The most reliable protection from TB 
transmission in theatre is the correct use of a filtering facepiece respirator (FFR) with an N95 
filter which allows penetration of less than 5% of airborne particles, providing that it is 
properly selected, correctly donned forming an impenetrable seal on the user’s face and worn 
whenever exposed to potential airborne hazards.12 
 
Guidelines from the World Health Organisation and the Centers for Disease Control and 
Prevention recommend that HCWs who work in a high risk environment for TB exposure, 
should use “fit tested” FFRs. Fit tests aim to assess and correct the user’s donning technique 
and to identify those who have an inadequate fit with a specific size or model of 
respirator.11,13,14 
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Anaesthetists are especially vulnerable due to their proximity to the airways of patients with 
potentially undiagnosed TB and their involvement in procedures that cause aerosolisation of 
infectious droplets.15 Incorrect use of the FFR, such as poor compliance, improper donning 
technique or an inadequate seal causing inward leakage, may put the user, in this case the 
anaesthetist, at risk.16 Compliance is a multifactorial issue, of which comfort of the FFR is an 
important factor.17,18 
 
The practice with regard to compliance, comfort, donning technique and fit of FFRs by 
anaesthetists from the Department of Anaesthesiology at the University of the Witwatersrand 
was not known. A two part study was undertaken which aimed to describe the anaesthetists’ 
compliance and comfort when using FFRs, the adequacy of their donning technique and the 
outcome of formal fit tests.  
 
Methods 
The study design was prospective, descriptive and contextual. Approval was obtained from 
the University of the Witwatersrand Human Research Ethics Committee and other relevant 
authorities prior to commencing the study.  
 
Part 1: a three sectioned anonymous, self-administered questionnaire was completed in the 
department. After an extensive review of the literature the two published questionnaires 
developed by Bryce et al were deemed the most appropriate.19 The comfort questionnaire was 
modified as follows, two statements identified in the literature were included, the Likert scale 
was changed to a more suitable four points instead of six and a review panel recommended 
the original negative statements be changed to generate a discomfort score for clarity. Thus a 
higher score on the comfort scale indicates more discomfort. The questionnaire was then 
51 
 
reviewed by senior consultants in the department to ensure validity for the South African 
context as the original questionnaire was used in a developed country. The final three 
sections were demographics, five statements concerning compliance on a six point Likert 
scale and seven statements concerning comfort on a four point Likert scale. The compliance 
score was out of 25 and the comfort score out of 21.  
At the time of the study it was known that there were 214 eligible anaesthetists in the 
department, however 64 (30%) were inaccessible due to leave or out of town rotations. The 
accessible anaesthetists (N=150) were approached at departmental academic meetings and a 
response of more than 80% was targeted using convenience sampling. Questionnaires were 
returned into a sealed box and the completed questionnaire implied consent. Consultants were 
termed “senior anaesthetists” and medical officers and registrars “junior anaesthetists”. 
 
Part 2: a pilot study was conducted to determine the adequacy of 20 anaesthetists’ donning 
technique and the outcome of a fit test. A room in the theatre complex of Charlotte Maxeke 
Johannesburg Academic Hospital (CMJAH) affiliated to University of the Witwatersrand was 
used.  Currently this hospital has only one model of FFR for use in the operating theatre 
(Quali-Med Medical & Safety Equipment CC Edenvale, South Africa) and this model is only 
available in one size. 
 
Stratified random sampling, using pregenerated random numbers between 1 and 1 000 000 
from the website random.org, was utilised to compile a sampling frame for each gender of the 
anaesthetists in the department at CMJAH.20 The first 10 males and 10 females on the list 
were invited to participate. The exclusion criteria included participants with facial hair which 
could prevent a seal, who were claustrophobic, had a medical condition that precluded them 
from wearing a FFR, had a problem with taste, a blocked nose or a known sensitivity to 
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denatonium benzoate (Bitrex® Edinburgh, UK). Bitrex® is an internationally approved safe 
“taste aversive agent” used in household liquids.21 If a selected participant refused or was 
excluded, the next participant of the same gender on the randomisation list was approached 
and invited to take part in the study. Part 2 of the study took place over three days. 
 
Twenty participants gave written consent and refrained from eating, drinking or smoking for 
30 minutes prior to their appointments. A hood with a hole in front of the breathing zone 
(called the fit test enclosure) was placed over the participant’s head and shoulders. Taste 
screening was performed with the participant’s eyes closed. A fine mist of the threshold 
check solution (pre-prepared 27 mg of Bitrex® diluted to 200 ml in 5% saline) was nebulised 
into the fit test enclosure. If the participants detected the bitter taste while breathing with their 
mouths slightly open and tongues extended, they could continue the test.  
 
A single assessor (MN) scored the participants’ donning technique of a disposable respirator 
according to eight criteria (summarised in Table 3 of the results). Thereafter training was 
given to ensure that the FFR was donned according to the manufacturer’s instructions.  
A fit test according to the Occupational Safety & Health Administration Standard 1910.134 
instructions was performed by one author (MN), using a fit test kit from Sperian Protection® 
(Honeywell International Inc. New Jersey, United States) with Bitrex® solution (337.5 
milligrams of Bitrex® diluted to 200 ml in 5% saline.) 22  
 
Each participant was instructed to don the fit test enclosure while wearing the correctly 
donned FFR. The Bitrex® solution was introduced into the fit test enclosure with a nebuliser 
while the participant breathed normally. The participant was then instructed to breathe 
deeply, move the head from side to side, move the head up and down, count out loud, bend 
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over and then breathe normally again.22 If the participant did not detect the bitter taste, the 
test was passed. However if Bitrex® was tasted at any point during these exercises the test 
was stopped and the participant was deemed to have an unacceptable fit and therefore failed 
the fit test. The bitter taste caused an almost involuntary reaction from the participants, 
making false results unlikely. 
 
Data analysis 
The data was analysed using Stata version 13.1 (StataCorp) statistical programme. 
Descriptive and inferential statistics were used. 
 
Part 1: data on the Likert scale are reported on both the ordinal and interval level. The 
summated data on the compliance and comfort scores were normally distributed and reported 
as means with standard deviations (SD). However data from individual statements were 
skewed and reported as medians with interquartile ranges (IQR). The options on the Likert 
scales were amalgamated into categories (as shown in Figures 1 and 2). The compliance of 
senior anaesthetists versus junior anaesthetists as well as the comfort of males versus females 
were compared using independent T-tests. 
 
Part 2: medians and ranges as well as frequencies and percentages were used to describe the 
donning technique. A frequency and percentage were used to describe the outcome of the fit 
test. 
 
Results 
Part 1: of the 152 questionnaires distributed 140 (92.1%) were returned, representing 65.4% 
of the 214 members of the department and a 92.1% response rate.  
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Ninety three (67.1%) participants were female, 53 (37.9%) were senior anaesthetists 
(consultants), and 87 (62.1%) were junior anaesthetists consisting of 61 (43.6%) registrars 
and 26 (18.6%) medical officers. 
Fourteen (10%) participants indicated that they have never used a FFP before and were 
therefore excluded from further analysis. The mean compliance score for the remaining 126 
(90%) participants was 14.5 (SD 5.02, 95% CI 13.60 - 15.35) out of 25 ranging from 3 - 25. 
Table 1 shows the compliance score results for individual statements. Figure 1 is a 
representation of the amalgamated Likert scale categories for each statement. 
 
Of the 14 participants who indicated that they have never used a FFR, 11 were senior 
anaesthetists. The mean compliance score of the remaining senior anaesthetists (n=42) using 
FFRs was 15.7 (SD 5.16, 95% CI 14.18 - 17.30) and for the junior anaesthetists (n=84), 13.5 
(SD 4.88, 95% CI 12.48 - 14.58), with ranges of 3 - 25 and 4 - 25 respectively. This 
difference was significant (P = 0.046).  
 
The mean discomfort score was 9.9 (SD 3.98, 95% CI 9.19 - 10.58) out of 21 ranging from 1 
- 18. Table 2 shows the discomfort scores for individual statements. The amalgamated Likert 
scale categories for each statement are represented in Figure 2. Not a single participant found 
the FFR 100% comfortable, although two participants scored a total of 1 out of 21 (thus 
scoring the FFR to be mostly comfortable). 
 
Females scored a mean of 10.5 (SD 4.1, 95% CI 9.63 - 11.36) range 1 - 18, making them 
more uncomfortable (P = 0.01) than the males who scored a mean of 8.5 (SD3.30 95% CI 
7.50 - 9.57) range 3 - 15.  
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Part 2: in total 24 participants were randomised as 4 were excluded due to facial hair, a 
blocked nose, claustrophobia and failing the sensitivity test. The median score for the 
donning technique was 6 (range 4 - 8) out of 8. Table 3 shows the donning technique results. 
Six (30%) participants passed the fit test. Of the 10 males, 5 (50%) passed, however only 1 
(10%) of the 10 females passed.  
 
Discussion 
This two part study explored how respiratory protection fails anaesthetists due to their own 
poor compliance, possibly as result of discomfort, with FFR use; as well as poor donning 
technique and ultimately poor fit with the FFR itself.  
 
The summated compliance score of 14.5 (58%) out of 25 in our study is lower than the 21.5 
(86%) found by Bryce et al in Canada.19 Our participants consistently scored lower than the 
participants in the Canadian study on every individual compliance statement. This is a 
concerning finding as TB is more prevalent in South Africa than in Canada. Biscotto et al 
randomly observed 145 HCWs in a Brazilian hospital between December 2000 and March 
2001.16 They found that only 25% of HCWs used FFRs for intubation and that only 20% used 
an FFR when performing a potentially infectious aerosol producing procedure. Self-reported 
questionnaires, such as used in our study, likely overestimate compliance when compared to 
direct observational studies. 
 
Eleven (78.6%) of the 14 participants in our study who indicated that they have never worn 
an FFR before were senior anaesthetists. Adeleke observed, in two clinics in Khayelitsha, that 
HCWs were influenced by their colleagues’ personal protection practices.17 Harrington 
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mentions that HCWs feel marginalised and stigmatised when using personal protective 
equipment.23  
 
Bryce et al investigated four statements concerning comfort on a six point Likert scale.18 
Unfortunately our summated discomfort score of 9.9 out of 21 cannot be directly compared to 
their “comfort score” of 13.6 out of 20, due to structuring of the statements and the way 
results were reported (they used means and SDs, whereas ours are reported as medians and 
IQRs). Their participants indicated a mean score of 3.2 (SD 1.3) out of 5 for the statement 
“The N95 respirator is comfortable.” In our study the median (IQR) score for the statement 
“The N95 respirator is uncomfortable” was 2 (2 - 3) out of 3, with only 15 (11.9%) 
participants never or seldom find the FFR uncomfortable (Figure 2). It appears that the 
participants in the study by Bryce et al found respirators more comfortable than participants 
in our study.18 This may be because there was a selection of FFRs available. In the study by 
Baig et al 24% of participants found the FFR to be comfortable most of the time or always 
(N=149).24  
 
In our study 58 (46%) participants stated that the FFR never or seldom makes them short of 
breath and 55 (43.7%) found that the FFR never or seldom makes them hot and sweaty, 
which is more than Baig et al found with 36% and 20% respectively not reporting shortness 
of breath and rarely or never experiencing an increase in facial temperature when wearing the 
FFR.24 Thirty one (24.6%) of our participants reported that the FFR never or seldom makes it 
difficult to communicate, which is similar to 22% of those in Baig et al’s study.24 Adeleke 
found that HCWs sometimes neglected personal protective equipment, despite dreading TB 
infection, because of discomfort, feeling smothered and difficulty in breathing when using the 
FFR.17  Other complaints reported by this author include the FFR makes one feel hot, it is a 
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communication barrier and proper donning and doffing take a long time. Discomfort of using 
FFRs appears to be prevalent and as such may pose a safety issue. 
 
Gender was found to be significant in our study with males being more comfortable with 
wearing FFRs than females. This is similar to the findings by Baig et al24. A FFR fit test 
trainer from a FFR manufacturing company claims that due to make-up, FFRs make females 
feel sweaty and sticky and may result in a rash. She advises females to remove their make-up 
before donning the FFR. 25  
 
The median score for the donning technique was 6 out of 8. One (5%) participant achieved 8 
out of 8 for adequacy of the donning technique. This participant, and another who achieved 7 
out of 8 had received formal training on donning the FFR in preparation for an Ebola 
outbreak in 2015. No other participant received formal training. 
 
Lee et al recommended that the National Institute for Occupational Safety and Health should 
specify that a minimum of 90% of randomly chosen users pass the fit test as a criteria for a 
certified FFR brand to be utilised in the implementation of an infection control program.26 
After donning the FFR adequately, 6 (30%) participants passed the fit test in our study. 
Biscotto et al observed facial leakage in 39% of participants, even though all of them 
received prior training and fit testing.22 Fit testing results are usually better in a controlled 
setting such as in our study than when working in the field. In the study by Bryce et al 217 
participants were fit tested with three different models of FFRs, but only 150 (69.1%) 
passed.19 The discrepancy in pass rates between our study and these two studies can possibly 
be due to us having only one model and one size of FFR available.   
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In our study half the male participants, but only one (10%) female passed the fit test. The 
difference was statistically insignificant (P=0.05), possibly because of the small sample size. 
McMahon et al fit tested 1271 HCWs.27 The fit test pass rate for their initial selection of FFR 
was 95.1% in males and 85.4% in females, a statistically significant difference. The study 
emphasises that women need a more extensive selection of FFRs options. Lee et al did 
however not find a difference in fit test pass rates between genders.26 
 
The large percentage that failed the fit test leads to the conclusion that more than one 
respirator model and size should be available. “One size does not fit all”.28 FFRs are designed 
based on the anthropometric data of facial characteristics and sizes obtained from large 
numbers of people grouped into “respirator fit test panels”.28 These panels were historically 
compiled by the National Institute for Occupational Safety and Health from American air 
force data.29, 30 Zhuang et al reported that previous fit test panels underrepresent the facial 
dimensions of females and non-Caucasians. 31 Spies et al conducted a preliminary study on 29 
South African volunteers from both genders and different races with a variety of facial 
characteristics.28 Repeated quantitative fit testing achieved satisfactory fit in only 4 (13.8%) 
participants with a single size and model FFR.  
 
The contextual design may limit the extent to which our results can be generalised to other 
contexts. Compliance is best tested by direct observation and not by self reporting. However 
for the scope of this study it was more appropriate to do self reporting due to cost, time and 
resource constraints. This methodology does not accurately reflect true compliance, although 
given the anonymous nature of the questionnaire participants are likely to answer truthfully 
about their own perception of how compliant they are.  
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The direct observation of the donning technique may influence findings as participants were 
aware of being observed. Some participants mentioned that there are no mirrors in theatre and 
thus it is a futile exercise to check FFR fit in a mirror. They requested that this statement be 
removed from the scoring of the donning technique or that mirrors be installed. 
 
In conclusion, poor compliance should be addressed especially since there is such a high 
incidence of TB in South Africa. Formal training of anaesthetists on FFR donning and use is 
required. It is possible that more choice of FFR models and sizes may improve comfort and 
thereby improve compliance, both of which were poor in this study. The feasibility of regular 
fit testing of the anaesthetists in this department should be investigated. Research with a 
larger study group is required. The reliance on a single size and model of FFR in this 
department should be reconsidered. 
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Tables 
Table 1 Compliance score (Likert scale 0-5) 
 Statement (n=129) Median  IQR 
1. I wear an N95 respirator when there is the possibility 
of an infectious airborne disease.  
3 2 - 4 
2. I perform a self-fit check after putting on my N95 
respirator.  
1  0 - 4 
3. I wash my hands before removing my N95 respirator.  1  0,25 - 5 
4. I discard my N95 respirator immediately after use.  5  3 - 5 
5. I take my N95 respirator off after I leave the room. 4  3 - 5 
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Table 2 Comfort score (Likert scale 0-3) 
 Statement (n=126) Median IQR 
1. The N95 respirator is uncomfortable. 2 2 - 3 
2. The N95 respirator makes me short of breath.  2 1 - 2 
3. The N95 respirator makes me claustrophobic. 2 1 - 2 
4. The N95 respirator makes me feel dizzy. 0 0 - 1 
5. The N95 respirator makes it difficult to communicate. 2 2 - 2 
6. The N95 respirator gives me a rash. 0 0 - 0 
7. The N95 respirator makes me hot and sweaty.  2 1 - 2 
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Table 3 Donning technique results 
 
 
 
 
 
  
 Criteria (n=20) Correct n 
1. Chin placement 19 
2. Strap tension 18 
3. Upper strap placement 18 
4. Lower strap placement 11 
5. Nasal bridge fit 15 
6. Respirator fixed (does not slip) 20 
7. Evaluate respirator fit and position in mirror 14  
8. Perform a self-fit check 4 
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Figures 
 
Figure 1 Compliance scores reported as ordinal data 
 
Figure 2 Comfort scores reported as ordinal data 
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Section 4: Appendices  
4.1 Ethics clearance 
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4.2 Post graduate committee approval 
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4.3 Approval from the Chief Executive Officer CMJAH 
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Section 5: Annexure 
Proposal 
5.1   Introduction  
Tuberculosis (TB) remains a far-reaching conundrum. Globally there were 8.6 million new 
cases of TB according to an estimation by the World Health Organisation (WHO) in 2012. (1) 
Seventy-five percent of these cases were in the African region and an estimated 450 000 
new cases of active TB were diagnosed in South Africa in 2013.  
HIV and TB are symbiotic co-epidemics. (2, 3) In 2012 73% of patients with TB were also HIV 
positive according to the South African Department of Health. (4) It is estimated that 10% of 
patients newly diagnosed with HIV have undiagnosed TB. (5) 
The emergence of multi-drug resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-
TB) pose a danger to the public (5) and especially to healthcare workers (HCWs). (6, 7) 
Worldwide TB has been regarded as an occupational health risk to HCWs for almost a 
century. (8, 9) In South Africa the overall prevalence of TB among HCWs was found to be 5 
% in 2009. (10)  
The customary prevention of TB transmission in healthcare facilities is accomplished by 
three levels of control measures. (11, 12) The first level is termed administrative controls. 
This includes education about cough hygiene and early diagnosis, isolation and treatment of 
patients with active disease. Secondly environmental or architectural controls are directed 
at reducing the number of airborne, infectious droplets. These measures include natural or 
mechanical ventilation systems, extractor turbines, sunlight or ultraviolet irradiation, (13, 
14) high-efficiency particulate air filters on exhaust air outlets and negative air ionization. 
The third level is the correct and consistent use of personal respiratory protection devices. 
(15) 
Direct sunlight and ultraviolet light kill the tubercle bacilli. For that reason most 
transmission happens in dark and poorly ventilated areas where droplet nuclei can stay 
suspended for up to four hours. (16) Both administrative and environmental transmission 
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control measures are extremely difficult and expensive to achieve in the operating room. 
This author is of the opinion that the most reliable method of protection from TB 
transmission available to HCWs in the operating theatre is consistent and correct use of 
disposable personal respiratory protection devices. 
The universally recommended respiratory protection device for protection against TB 
transmission is a filtering facepiece respirator (FFR) with an N95 filter. N95 filters are not oil 
resistant and will filter at least 95% of airborne particles (17). The filter is only effective if it 
forms an impenetrable seal on the user’s face.  
It is essential that the FFR is correctly selected, fitted and donned and worn the whole time 
that the user is exposed to potential airborne hazards. The idea behind fit testing is to test 
and correct the user’s donning technique, and then to identify that small percentage of 
individuals who will have an inadequate fit with the first model respirator they try on (18). 
Anaesthetists are a vulnerable group of HCWs due to their proximity to high risk procedures 
on patients with potentially undiagnosed TB. Procedures that cause coughing result in 
aerosolisation of droplets containing the infectious tubercle bacilli. (19) 
Guidelines from the WHO (1) and Centers for Disease Control and Prevention (15) 
recommend the use of fit tested FFRs for those HCWs who work in high exposure risk areas.  
The Infection Prevention & Control Protocol Isolation Precautions of Charlotte Maxeke 
Johannesburg Academic Hospital (CMJAH), endorsed by the Gauteng Province Department 
of Health mention that FFRs should be worn by HCWs caring for a patient with suspected or 
confirmed MDR- or XDR-TB. (19) The revised infection control guidelines were due for 
distribution in May and June 2016, but were not yet available at the time of printing. 
Due to the nature and environment of their occupation, anaesthetists who have access to 
the recommended N95 FFR are still at risk of TB transmission, if there is a face leak between 
the FFR and the skin, or if compliance with the use of the FFR in applicable situations is poor. 
Comfort is a factor that also influences compliance. (21, 22)  
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5.2  Problem statement 
 
In the case of anaesthetists the only reliable defence against occupational TB is the 
appropriate use of personal respiratory protection devices. At the CMJAH an N95 FFR is 
used, but this can only be effective if the right size and model is correctly donned, forms an 
impenetrable seal on the wearer’s face and the wearer is compliant with use in relevant 
situations. The practice with regard to the compliance and comfort of the use of FFRs by 
anaesthetists from the Department of Anaesthesiology at the University of the 
Witwatersrand (Wits) and the fit of the FFRs that is available at hospitals affiliated to the 
department is not known. 
 
5.3  Aims and objectives 
 
This study will be done in two parts. 
 
5.3.1 Part I 
The aim of Part I of the study is to describe the compliance and the comfort of use of the 
FFR of the anaesthetists in the Department of Anaesthesiology at Wits. 
The primary objectives of Part I of the study are to: 
 describe the compliance of anaesthetists with use of the FFR 
 describe the comfort of anaesthetists wearing the FFR.  
The secondary objectives of Part I are to: 
 compare the compliance with FFR use of consultants to that of junior anaesthetists 
 compare the comfort of FFR use between males and females. 
5.3.2 Part II 
Part II will be a pilot study with the aim of describing the FFR donning technique and the 
outcome of the fit test of the anaesthetists in the Department of Anaesthesiology at CMJAH. 
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The primary objectives of Part II of the study are to: 
 describe the adequacy of the FFR donning technique 
 describe the outcome of the FFR fit test. 
The secondary objective of Part II of this study is to compare FFR fit test outcome with 
gender. 
 
5.4  Research assumptions 
 
The following definitions will be used in the study. 
Anaesthetist: is any qualified doctor working in the Department of Anaesthesiology 
including medical officers, registrars and consultants.  
Medical officer: a qualified doctor practising in the Department of Anaesthesiology under 
specialist supervision. Medical officers with more than 10 years of anaesthetic experience 
are career medical officers and are considered as consultants. 
Registrar: a qualified doctor who is registered with the Health Professionals Council of South 
Africa as a trainee anaesthetist. 
Consultant: an anaesthetist who is registered with the Health Professionals Council of South 
Africa as a specialist anaesthesiologist.  
Junior anaesthetists: include medical officers and registrars. 
Compliance: determined according to the compliance questionnaire (Appendix A) adopted 
from the published questionnaire by Bryce et al. (23) 
 Adequate technique: to demonstrate adequate technique the participant needs to score 
100% of the criteria on the technique score sheet (Appendix B). 
Filtering facepiece respirator (FFR): the FFR used in this study is the specific model (FFP2 
respirator by Quali-Med Medical & Safety Equipment CC) procured by CMJAH infection 
control department for protection against nosocomial TB at the time of the study. This FFR 
is only available in one size. It is colloquially known as an “N95 mask”. 
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Fit test kit: the kit used in the fit test is from Sperian Protection® (Honeywell International 
Inc. New Jersey, United States) qualitative fit test apparatus, as recommended by the 
representative for respiratory protection devices from the company Quali-Med. 
 
5.5  Demarcation of study field 
Part I of the study will be conducted in the Department of Anaesthesiology, affiliated to the 
Faculty of Health Sciences of the University of the Witwatersrand. The staff complement of 
the department is 75 consultants, 112 registrars and 27 medical officers. 
Part II of the study will be conducted in the theatre complex of CMJAH affiliated to the 
Department of Anaesthesiology at the University of the Witwatersrand.  CMJAH is a 1200 
bed central hospital. The hospital has 23 theatres. On average 23 000 cases are done 
annually. The anaesthesia staff complement at this theatre complex is 25 consultants and 37 
registrars and medical officers. 
 
5.6  Ethical considerations 
Approval to conduct the study will be sought from the Human Research Ethics Committee 
(Medical) and the Postgraduate Committee of the University of the Witwatersrand. 
Permission to conduct Part II of the study at CMJAH will be obtained from the Chief 
Executive Officer prior to commencement of the study (Appendix C). 
For Part I participants will be approached at the departmental academic meetings. The 
study will be explained to them and they will be invited to take part. The researcher will 
distribute an information letter (Appendix D) and the questionnaires (Appendix A). The 
participant’s consent is implied if the questionnaire is returned.  
Anonymity will be ensured in Part I by collecting data on questionnaires without identifying 
information. Confidentiality will be ensured in Part I, because only the researcher and 
supervisors will have access to the raw data. If compliance with FFR use is found to be poor 
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based on the questionnaire, a training session will be organised to improve compliance with 
respiratory protection amongst members of the department. 
For Part II of the study participants will be randomly selected. Those participants who have 
been selected will be approached in person, the study explained and they will be invited to 
take part.  An information letter (Appendix E) will be given to them to read and if they 
agree, they will be asked to sign the consent form (Appendix F). If someone chooses to 
decline participation in the study the next person on the randomised list will be approached 
and invited to part take. 
Anonymity will not be possible in Part II of the study as the researcher will conduct the test, 
however the data generated will be documented and reported anonymously. The 
participants will be assured that there will be no negative consequences for participation 
regardless of the outcome. Confidentiality will be ensured in Part II of the study, because 
only the researcher and supervisors will have access to the information and raw data. The 
Head of Department of Anaesthesiology will be notified if: 
 The donning technique is inadequate to organise training. 
 If it is found that a number of participants do not pass the fit test despite adequate 
training in the donning technique, the appropriateness of the brand procured should 
be investigated. Importantly only group, not individual data will be reported to the 
Head of Department of Anaesthesiology. 
The fit test is performed with the use of aerosolised Bitrex® spray. Bitrex® has been 
routinely used as a taste aversion agent in household liquids to deter children from drinking 
them since its approval in the United Kingdom and the USA in the early 1960s. (24, 25) 
Participants will be asked to close their eyes whenever the solution is sprayed. 
Data will be stored securely for six years after completion of study. The study will be 
conducted according to the principles of the Declaration of Helsinki (26) and the South 
African Guidelines for Good Clinical Practice. (27) 
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5.7  Research methodology 
5.7.1   Research design 
 
According to Creswell (28) a research design is the framework that guides the assumptions 
about variables established from the literature review, the approach to the appropriate 
investigation and decisions about data collection methods. 
 
A prospective, contextual, descriptive research design will be followed in this study. 
 
A prospective study according to Brink et al (29) is defined as: “data about a presumed 
cause are first collected and then the effect or outcome is measured.” The study is 
prospective as data will be collected at the outset and thereafter the outcome will be 
measured. 
 
The study is contextual as it is concerned with understanding the true immediate 
circumstances, environment and context, with which the study problem is associated. (30) 
This study will be conducted contextually in the Department of Anaesthesiology affiliated to 
the University of the Witwatersrand.  
 
A descriptive study gives an account of a singularity or occurrence in a study sample. The 
account is particular to that sample and may be unrelated to the larger population. 
Variables are depicted and explored as they exist naturally in order to provide a complete 
description of the study sample, and are not manipulated by the researcher. According to 
Brink et al (29) data for descriptive studies are classically collected by “structured 
observation, questionnaires and interviews or survey studies.”   
 
Research methodology for Part I and Part II of the study will be discussed separately.   
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Part I 
Study population 
The study population consists of the anaesthetists working in the Department of 
Anaesthesiology. 
Study sample 
Sampling method 
In this part of the study a convenience sampling method will be used. Convenience sampling 
is the same as “accidental” or “availability sampling”. (29) For Part I of the study readily 
accessible participants will be invited to partake at the departmental academic meetings.  
Sample size 
At the time of the study it was known that there were 214 eligible anaesthetists, but at the 
time of data collection it was calculated that approximately 30% of the anaesthetists would 
be inaccessible due to leave, out of town rotations etc. Of the 150 available anaesthetists a 
response rate of 120 (80%) will be targeted.  
Inclusion and exclusion criteria 
All anaesthetists working in the Department of Anaesthesiology meet the inclusion criteria 
of the study. 
Exclusion criteria: 
 anaesthetists who refuse to take part in the study 
 anaesthetists who are on annual leave, special leave or sick leave 
 blank questionnaires. 
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Collection of data 
Research questionnaire 
Following an extensive literature review, a data collection sheet with a three section 
questionnaire (Appendix A) was compiled for Part I of the study. Section 1 consists of the 
demographics of the participants, Section 2 is the compliance score and Section 3 is the 
comfort score.  
Sections 2 and 3 are adaptations from published questionnaires on compliance and comfort 
developed by Bryce et al. (23) The comfort questionnaire was modified as follows, two 
statements identified in the literature were included, the Likert scale was changed to a more 
suitable four points instead of six and a review panel recommended the original negative 
statements be changed to generate a discomfort score for clarity. Thus a higher score on the 
comfort scale indicates more discomfort.  
The adapted questionnaire was reviewed by three senior consultants in the Department of 
Anaesthesiology to ensure that it is valid in the South African context as the original 
questionnaire was used in a hospital in a developed country. Suggested changes were 
incorporated. The final three sections were demographics, five statements concerning 
compliance on a six point Likert scale and seven statements concerning comfort on a four 
point Likert scale. The compliance score was out of 25 and the comfort score out of 21. The 
method of using questionnaires in this study sample is appropriate as the participants are 
educated and cooperative with research. (29) 
In Section 1 the following demographics will be collected:  
 professional designation 
 gender 
Section 2 will comprise of five statements concerning compliance using a six point Likert 
scale. Section 3 will consist of seven statements concerning comfort using a four point Likert 
scale. 
Data collection 
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Data will be collected on a Wednesday afternoon at the departmental academic meetings. 
The convenor of the academic meeting will be approached and asked for permission to 
address the meeting. The study will be introduced, followed by an explanation of the aims 
and objectives. The participants who decide they want to partake in the study will receive 
the information letter and a questionnaire. The questionnaires will be numbered to keep 
track of the response rate. The researcher will be present to distribute the questionnaires 
and to assist with any queries. Participants are granted 10 minutes to complete the 
questionnaire. A returned questionnaire will imply consent and the participants will place 
the completed questionnaires in a sealed collection box. 
 
Data analysis 
Data will be captured on Microsoft Office Excel® 2011 spread sheets for analysis. 
Anaesthetists will be scored according to a total score as well as on individual questions. The 
categorical variables will be described using frequencies and percentages. The Likert scales 
for compliance and comfort will be interpreted as interval data. The data will be analysed on 
Stata version 13.1 (StataCorp) statistical programme. Descriptive statistics will be used to 
describe the data. The compliance of senior anaesthetists will be compared to that of junior 
anaesthetists and the comfort scores of males and females will be compared using T-tests. A 
p- value of less than 0.05 will be considered as statistically significant.  
 
Part II 
Study population 
The study population consists of the anaesthetists working in the Department of 
Anaesthesiology at CMJAH. 
Study sample 
Sampling method 
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The sampling method for Part II of the study is stratified random sampling according to the 
definition by Polit and Beck. (31) For this sampling method “the population is first divided 
into two or more strata”. In this study the sample will be divided by gender to ensure that 
an equal number of males and females are represented. Only after stratification will the 
sampling frame be randomised. The sampling frame is “the technical name for the list of 
elements from which the sample will be chosen.”(31) Randomisation is the process by which 
each member of the population has an equal opportunity of being chosen. 
An alphabetical list of names of anaesthetists working at CMJAH will be requested from the 
Head of Department. The names on the list will be divided according to gender resulting in a 
sampling frame that comprises two lists. 
With the help of the true random number service on the website random.org (32) a 
randomly selected number from 1 to 1 000 000 will be allocated to each name on the list of 
male anaesthetists and the same for each name on the list of female anaesthetists. The 
website random.org is operated by Randomness and Integrity Services Ltd. and it generates 
randomness using atmospheric noise and not algorithms or formulae.  
It is important to use 1 000 000 possibilities, even though the sampling frame is only 63 
anaesthetists to avoid allocating the same number twice. The randomly allocated numbers 
will be arranged in ascending order. The first 10 numbers on each list with the 
corresponding name of the anaesthetist will make up the study sample. If an anaesthetist 
on the list is excluded based on the inclusion and exclusion criteria (for example the 
anaesthetist has a beard), the same technique will be used to select another participant 
from the remainder of the sampling frame. 
Sample size 
For Part II a pilot study will be done with 20 anaesthetists working at CMJAH. A pilot study is 
a miniature version of a major study to assess feasibility. This can help the researcher to 
identify potential difficulties and snags in the data collection process that can be avoided or 
addressed in the actual study. (29) 
Inclusion and exclusion criteria 
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The inclusion criteria for this part of the study are: 
 anaesthetists working in the Department of Anaesthesiology at CMJAH 
 who consent to take part in the study. 
The exclusion criteria of Part II of this study are participants who: 
 have facial hair that may hinder a proper seal (a beard, big moustache or sideburns 
that come between the skin and the FFR) 
 wear apparel that will interfere with the seal of the FFR and that cannot be removed 
(for example external braces or synthetic hair extensions that extend behind the 
person’s head prohibiting proper strap placement) 
 have a medical condition such as shortness of breath, that precludes them from 
wearing a FFR 
 have claustrophobia 
 have a problem with tasting bitterness 
 have a blocked nose 
 have a known sensitivity to Bitrex®. 
Collection of data 
Data collection sheet 
A data collection sheet (Appendix B) was compiled consisting of: 
 demographics (gender) 
 technique score sheet 
 training received 
 fit test outcome. 
The technique scoring sheet and the fit test were adapted from the mandatory fit testing 
protocols as set out in the subpart on personal protective equipment in the Occupational 
Safety & Health Administration (OSHA) Standard 1910.134 Appendix A as published by the 
United States Department of Labor. (33) 
Data collection process 
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Once the 20 members have been selected from the sampling frame they will be invited 
personally to participate on the three mornings of the study. They will be issued with the 
information letter (Appendix E) and consent form (Appendix F). If they agree to take part, 
time slots will be allocated to the 20 participants. They will be requested not to eat, chew 
gum, smoke or drink anything other than water for 30 minutes before their time slot. 
Demographical data on the gender of the participants will also be documented. Data on the 
technique of the participants donning the FFR will be directly observed by the researcher. 
The participant will know that they are being observed but they will not know the scoring 
criteria. 
After each participant has been scored on his or her technique of donning the FFR, he or she 
will receive individual training on the manufacturer’s donning recommendations in an 
attempt to get the best fit possible. Thereafter the fit test is performed and the researcher 
will document the outcome of each test as pass or fail.  
The fit test is performed by the researcher using a fit test kit (figure 5.1) that contains 
Bitrex® as the test solution. 
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Figure 5.1: The fit test kit (34) 
The fit test kit contains a hood (the “enclosure”) with a 1.9 cm hole in front of the 
participant’s nose and mouth area. There are two nebulisers and two bottles in the kit, one 
with the standardised diluted Bitrex® (Denatonium Benzoate) threshold check solution and 
the other with the Bitrex® indicator solution at the normal concentration. 
Firstly it will be ascertained that the participant can taste the Bitrex®. Taste threshold 
screening is performed with the threshold check solution, with the participant wearing the 
enclosure over the head and shoulders, but without wearing a FFR. The researcher shall 
spray a fine mist of the diluted Bitrex® solution into the enclosure with a nebuliser while the 
participant keeps his or her eyes closed. Only if the participant detects the bitter taste will 
he or she continue to the fit test.  
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The fit test is done with the participant wearing the FFR properly positioned and the 
enclosure donned. The indicator solution is nebulised into the enclosure while the 
participant breathes as indicated above. The participant will be guided through the 
following exercises (Figure 5.2): 
 breathe normally 
 breathe deeply 
 turn the head slowly from side to side 
 slowly move the head up and down 
 count out loud 
 bend over 
 breathe normally again. (35) 
 
Figure 5.2: The seven exercises (35)  
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If the participant does not report tasting the Bitrex®, the test is passed. However, if the taste 
of Bitrex® is detected at any point during the exercises, the fit is incorrect and the fit test 
failed.  
Data analysis 
The mean and standard deviation will be used to describe the results of technique score 
sheet if the data follow Gaussian distribution, or the median with interquartile ranges will 
be used if data do not follow the Gaussian distribution. A frequency and percentage will be 
used to describe the outcome of the fit test.  
As a secondary outcome the data from Part II of the study will also be compared in 
categories of fit test passed by males versus females using the Fishers Exact Test.  A p-value 
of less than 0.05 will be considered significant. 
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5.8  Significance of the study  
 
The emergence of MDR- and XDR-TB strains and the prevalence of HIV in South Africa make 
the ongoing battle against TB more relevant than ever. HCWs are disproportionately 
endangered (7, 19, 36). Even though administrative and architectural measures of 
preventing TB transmission are very effective, their application to a theatre environment are 
difficult and expensive. Due to the proximity of anaesthetists to the airways of patients with 
potentially undiagnosed TB presenting for surgery they are at risk of occupational TB 
infection. They are almost exclusively dependent on a perfectly fitting N95 FFR as their 
barrier of defence against occupational TB. The anaesthetist may still be at risk if there is 
leakage between the FFR and the skin, or if compliance with the use of the FFR in applicable 
situations is poor.  
 
The results from Part I of the study may influence current practice. If the results show that 
the anaesthetists have poor compliance with use of the FFR, this may be addressed by a 
training session to ultimately improve safety.  
 
If the results from Part II show that donning technique is poor this may be addressed at the 
same training session. If results from the fit test show that a number of participants failed 
the fit test despite adequate technique, the implication could be that either the model or 
size of FFR is incorrect for those individual participants. Currently in CMJAH no alternative 
size or model FFR is available. This information will be communicated to the Head of 
Department of Anaesthesiology. This may help to motivate the procurement of a choice of 
models of FFR in order to enhance the safety of anaesthetists at risk of TB transmission. This 
study may also motivate that more fit tests be done in the department. 
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5.9  Validity and reliability of the study 
The concept of validity is explained by Botma et al (37) as “the degree measurement reflects 
a true value”.  The concept of reliability is about the dependability, regularity and 
consistency of the results. (37) 
The validity and reliability of this study will be ensured by: 
 using an appropriate study design 
 using previously published questionnaires 
 using local experts to ensure face validity for the South African context 
 having a single data collector to guarantee uniform instructions and collection 
 analysing data with the assistance of a biostatistician. 
 
5.10  Potential limitations of the study 
According to Creswell (28) limitations are the potential weaknesses of the study. 
Part I of the study is limited by the convenience sampling method, as the population may be 
over or under represented. The contextual design may restrict the extent to which the 
results can be generalised to other contexts. 
The yield of questionnaires is limited to the response rate of participants, which may 
influence how representative the sample is.  
The limitations of the direct observation component of Part II of the study are that the 
researcher is present while the anaesthetists don the FFR. Their awareness of being 
observed while putting on the FFR may influence behaviour. They may take more care in 
donning the mask than they would in the real-life situation that happens in the operating 
room. 
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5.11  Project outline 
 
Activity May 
2015 
June 
2015 
August 
2015 
Nov 
2015 
Dec 
2015 
Jan 
2016 
Feb 
2016 
Mar 
2016 
April 
2016 
Proposal 
preparation 
         
Literature 
review 
         
Proposal 
submission 
         
Ethics and 
postgrad 
approval 
         
Data 
collection 
         
Data 
analysis 
         
Writing 
article 
         
Submission 
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5.12  Financial plan 
 
Statement Cost for 1 Number 
required 
Total 
Binding R50 2 R100 
Paper and printing R1 1000 R1000 
Test kit R4 357.74 1 R4357.74 
Filtering facepiece respirators R200 1 box R200 
Total   R5657.74 
 
The cost of paper and printing was incurred by the Department of Anaesthesiology.  
The fit test kit ass borrowed from Quali-Med. 
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Appendix A:  Part I data collection sheet 
Anaesthetist compliance and comfort in use of N95 filtering facepiece 
respirator questionnaire 
Section 1: Demographics 
1. Please indicate your professional designation using an X: 
Consultant Career medical 
officer 
Registrar Medical officer 
 
2. Please indicate your gender:  
 
 
Section 2: Compliance with use of N95 filtering facepiece respirator questionnaire 
 
3. Have you ever used a filtering facepiece respirator to protect yourself against TB 
transmission? 
 
 
4.    If your answer for Question 3 is “Yes” please continue the questionnaire by indicating 
the statement most applicable to your current practice: 
  
Male Female 
Yes No 
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Compliance score  
Statement Never Almost 
never 
Occasion-
ally 
Often Almost 
always 
Always 
I wear an N95 respirator when there is 
the possibility of an infectious airborne 
disease. 
0 1 2 3 4 5 
I perform a self-fit check after putting on 
my N95 respirator. 
0 1 2 3 4 5 
I wash my hands before removing my 
N95 respirator. 
0 1 2 3 4 5 
I discard my N95 respirator immediately 
after use. 
0 1 2 3 4 5 
I take my N95 respirator off after I leave 
the room. 
0 1 2 3 4 5 
Section 3:  Comfort of N95 filtering facepiece respirator use score 
4. If your answer for Question 3 is “Yes”, please indicate the statement regarding how 
comfortable using the N95 filtering facepiece respirator is for you: 
Comfort score 
Statement Never Seldom Often Always 
The N95 respirator is uncomfortable. 
0 1 2 3 
The N95 respirator makes me short of breath. 
0 1 2 3 
The N95 respirator makes me claustrophobic. 
0 1 2 3 
The N95 respirator makes me feel dizzy. 
0 1 2 3 
The N95 respirator makes it difficult to communicate. 
0 1 2 3 
The N95 respirator gives me a rash. 
0 1 2 3 
The N95 respirator makes me hot and sweaty. 
0 1 2 3 
Thank you for taking the time to complete this questionnaire.  
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Appendix B:  Part II data collection sheet  
Demographics 
Gender: 
 
Criteria for adequacy of respirator fit technique score sheet 
Criteria Yes No 
proper chin placement 
inside FFR 
  
adequate strap tension   
adequate upper strap 
placement 
  
adequate lower strap 
placement 
  
fit across nasal bridge   
respirator remains fixed 
(does not slip) 
  
evaluate FFR fit and position 
in mirror 
  
perform a self-fit check   
Total out of 8   
Training received:  Yes No 
 
 
Outcome of fit test 
Outcome Pass Fail 
  
Male Female 
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Appendix C:  Letter to the CEO 
        501 Mentone Court 
44 Riviera Road 
Killarney 
2193 
5 July 2015 
To the Chief Executive Officer of Charlotte Maxeke Johannesburg Academic Hospital 
Dear Sir / Madam 
My name is Marthinet Niemandt and I am currently a registrar in the Department of 
Anaesthesiology. I would like to do a study with the title Use and fit of filtering facepiece 
respirators in a Department of Anaesthesiology. 
The aim of Part I of the study is to describe the compliance and the comfort of use of the N95 
filtering facepiece respirator of the anaesthetists in the Department of Anaesthesiology at 
Charlotte Maxeke Johannesburg Academic Hospital. The aim of Part II of this study is to describe 
the donning technique and fit test of the N95 filtering facepiece respirator of the anaesthetists 
in the Department of Anaesthesiology at Charlotte Maxeke Johannesburg Academic Hospital. 
I would like to request permission to investigate the objectives of the research proposal.  There 
will be no cost to the hospital as result of the study. 
Post-grad approval has been obtained. Ethical clearance (protocol number M150711) is pending 
CEO approval and corrections suggested by Human Research Ethics Committee (Medical) have 
been made.   
I thank you in advance 
 
Marthinet Niemandt 
0834756911 
marthinetniemandt@gmail.com 
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Appendix D: Information letter (Part I) 
          November 2015 
Dear colleague 
Hello, my name is Marthinet, I am a registrar in the Department of Anaesthesiology. This letter is an 
invitation to partake in my M Med research study titled: Use and fit of filtering facepiece respirators 
in a Department of Anaesthesiology. 
The last barrier of defence that anaesthetists can rely on to protect themselves from transmission of 
tuberculosis is the use of respiratory protection devices. In the Charlotte Maxeke Johannesburg 
Academic Hospital (CMJAH) a N95 filtering facepiece respirator is provided for this purpose. This 
measure is only effective if the right size and model is used appropriately. Comfort is an important 
factor that determines compliance with N95 filtering facepiece respirator use. 
I am doing a two part study. The aim of this part of the study is to describe the compliance and 
comfort in the use of the N95 filtering facepiece respirator of the anaesthetists in the Department of 
Anaesthesiology at CMJAH. 
Completing the questionnaire will imply consent to participate in the study. Participation is voluntary 
and anyone is free to withdraw from the study at any time without having to supply a reason.  
Questionnaires are anonymous as no identifying data will be asked of you. Once the questionnaires 
are completed, they will be placed in a sealed data collection box. It will take less than 10 minutes to 
complete the questionnaire. The process is completely confidential and only my study supervisors 
and I will have access to the raw data. 
If the results show poor compliance with the use of the filtering facepiece respirator that may put 
you at risk of acquiring TB at work, I shall organise a training session to educate the department on 
the correct use of the filtering facepiece respirator. 
The Human Research Ethics Committee (Medical) (protocol number M150711) and the Post-
graduate Committee of the University of the Witwatersrand have approved the study proposal. 
If you have any questions with regards to the study, please contact me on 083 475 6911 or 
marthinetniemandt@gmail.com. The chairperson of the Human Research Ethics Committee is Prof 
Cleaton-Jones. He can be contacted on 011 717 1234. 
Thank you for taking the time to read this letter. 
Yours sincerely 
 
Marthinet Niemandt 
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Appendix E:  Information sheet (Part II) 
          November 2015 
Dear colleague 
Hello, my name is Marthinet, I am a registrar in the Department of Anaesthesiology. This letter is an 
invitation to you to partake in my M Med research study titled: Use and fit of filtering facepiece 
respirators in a Department of Anaesthesiology. 
The last barrier of defence that anaesthetists can rely on to protect themselves from transmission of 
tuberculosis is the use of respiratory protection devices. In the Charlotte Maxeke Johannesburg 
Academic Hospital (CMJAH) a N95 filtering facepiece respirator is provided for this purpose. 
I am doing a two part study and the aim of this part of the study is to describe the donning 
technique and to do a fit test of the N95 filtering facepiece respirator with anaesthetists in the 
Department of Anaesthesiology at CMJAH. 
You will be excluded from the study if you: 
 have a medical condition such as shortness of breath or claustrophobia, that precludes 
you from wearing a N95 filtering facepiece respirator or a hood 
 feel that you have a problem with tasting bitterness 
 have a blocked nose 
 have a known sensitivity to Bitrex®. 
If you agree to participate, please choose a suitable 20 minute time slot on the sheet of paper 
supplied. Please do not eat, smoke, chew gum or drink anything other than water for 30 minutes for 
before your time slot as eating may affect your detection of the test solution. 
A threshold screen shall be performed to ascertain that you are able to detect the taste of the test 
solution. You will wear an enclosure (a hood with a 1.9 cm hole in front of your nose and mouth 
area) over your head and shoulders. I will ask you to close your eyes. I will then spray a fine mist of 
diluted test solution into the enclosure and ask you to breathe through a slightly open mouth with 
your tongue extended. I will ask you if you can detect the taste of the solution. 
Next I will ask you to don a N95 filtering facepiece respirator. While wearing the filtering facepiece 
respirator you will don the enclosure. I shall ask you to close your eyes again and spray the test 
solution into the hood. You will again be asked to let me know if you can detect the taste of the 
solution. I will give you very specific instructions about what is expected of you during the fit test. 
Participation is voluntary and anyone is free to withdraw from the study at any time without having 
to supply a reason. Anonymity will not be possible in this study as the researcher will conduct the 
test, however the data generated will be documented and reported anonymously. There will be no 
negative consequences for participation regardless of the outcome. Only the researcher and 
supervisors will have access to the information and raw data therefore ensuring confidentiality. 
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If the results show the N95 filtering facepiece respirator provided does not fit your facial features, I 
shall report this possible safety hazard to the Head of Anaesthesiology. 
The Human Research Ethics Committee (Medical) (protocol number M150711) and the Post-
graduate Committee of the University of the Witwatersrand have approved the study proposal. If 
you have any questions with regards to the study, please contact me on 083 475 6911 or 
marthinetniemandt@gmail.com. The chairperson of the Human Research Ethics Committee is Prof 
Cleaton-Jones. He can be contacted on 011 717 1234. 
Thank you for taking the time to read this information letter. 
Yours sincerely 
 
Marthinet Niemandt 
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Appendix F:  Informed consent letter for Part II 
Title: Use and fit of filtering facepiece respirators in a Department of Anaesthesiology  
(Part II) 
Principle researcher: Marthinet Niemandt 
Telephone number: 083 475 6911 
Email address: marthinetniemandt@gmail.com 
Department of Anaesthesiology 
Name of participant: ____________________________________________ 
Nature of research: Participant will be a test subject for the fit test with the filtering 
facepiece respirator. 
The study poses no risks to the participants. The potential benefits are that the participants 
will receive one on one training on the donning technique of the filtering facepiece 
respirator.   
 
I, (name)____________________________________, hereby agree to participate in the 
study titled Use and fit of filtering facepiece respirators in a Department of 
Anaesthesiology. 
I acknowledge that:  
 I have read this consent form and the information letter and I had the opportunity to 
ask questions about them 
 I agree to my results being used for research purposes on condition that my privacy 
is respected 
 I understand that I am under no obligation to take part in this study 
 I understand I have the right to withdraw from this project at any stage. 
 
Date: ____________________ 
 
Signature of participant: __________________________ 
Signature of principal investigator who sought consent: __________________ 
 
